Хроническая сердечная недостаточность мкб 0: I50. 0, I50. 1, I50. Год утверждения (частота пересмотра): 2020

жүктеу/скачать 1.54 Mb.

Pdf көрінісі

бет	73/88
Дата	21.03.2022
өлшемі	1.54 Mb.
	#456432

1 ... 69 70 71 72 73 74 75 76 ... 88

1.2 Клинические рекомендации

IIbC) (УУР А, УДД 2) [467,596-599].
Комментарии.Экстракорпоральные
системы
механической
поддержки
кровообращения,
использующие
центрифужные
нагнетатели, способствующие осуществлению циркуляции крови,
на основе исключительно магнитного поля, одобрены на срок

использования
до
30
дней,
демонстрируют
лучшие
гемодинамические показатели, обеспечивающие значительное
снижение частоты возникновения инсультов, отсутствие случаев
гемолиза и тромбоза насоса, статистически значимое улучшение
функционального статуса и качества жизни пациентов,
обеспечивают клиническое преимущество для восстановления
сократительных функций миокарда.

Критерии оценки качества
медицинской помощи
Таблица 16. Критерии оценки качества оказания
медицинской
помощи
пациентам
с
сердечной
недостаточностью.
№
Критерии качества
ЕОК
Уровень
убедительности
рекомендаций
доказательств
Уровень
достоверности
доказательств
Да/
нет
1
Выполнена
ЭКГ
в
12
отведениях
IA
В
3
2
Выполнена
прицельная
рентгенография
органов
грудной клетки
IA
В
3
3
Выполнена
эхокардиография
IA
В
3
4
Выполнен
биохимический
анализ крови (мочевина,
креатинин,
расчетная
скорость
клубочковой
фильтрации, калий, натрий,
глюкоза, билирубин, АЛТ,
АСТ)
IA
В
3
5
Выполнен общий анализ
крови
IA
В
3
6
Выполнен общий анализ
мочи
IA
В
3
7
Выполнено
определение
уровня натрийуретических
пептидов
(мозгового
натрийуретического
пептида/N-концевого
фрагмента
прогормона
мозгового
натрийуретического
пептида (NT-proBNP)
IA
А
1
8
У
пациентов
с
острой
декомпенсацией
СН
проведена
терапия
петлевыми
диуретиками,
при
необходимости
-
вазодилататорами
и/или
инотропными препаратами
и/или вазопрессорами
IC
В
3
9
Начат
подбор
терапии
иАПФ/АРА/
валсартан+сакубитрил**,
бета-адреноблокаторов
и
альдостерона
антагонистами
или
проведена коррекция их
дозы
согласно
существующим
рекомендациям
IA
А
1

Список литературы
1. Фомин И. В. Артериальная гипертония в Российской
Федерации – последние 10 лет. Что дальше? Сердце. 2007;6 (3):1–
6.
2. Ситникова М. Ю., А. В. Юрченко, Е. А. Лясникова, М. А.
Трукшина, Р.А. Либис, В.Ю. Кондратенко, Дупляков Д.В.,
Хохлунов С.М., Е. В. Шляхто. Результаты Российского
госпитального регистра хронической сердечной недостаточности
в 3 субъектах Российской Федерации. Кардиология, 2015; 55:10,
стр.13 – 21.
3. Фомин И. В. Эпидемиология хронической сердечной
недостаточности в Российской Федерации. В кн.: Хроническая
сердечная недостаточность [Агеев Ф. Т. и соавт.] – М.: ГЭОТАР-
Медиа, 2010. – c. 7–77
4. Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart
Failure survey programme a survey on the quality of care among
patients with heart failure in Europe. Part 1: patient characteristics
and diagnosis. Eur Heart J. 2003; 24 (5):442–463.
5. Lam C.S.P., Solomon S.D. The middle child in heart failure:
heart failure with mid-range ejection fraction (40–50%). Eur J Heart
Fail 2014; 16:1049–1055.5
6. Щербинина Е.В., Бадин Ю.В., Вайсберг А.Р., и.др. Динамика
этиологических причин формирования ХСН в репрезентативной
выборке Нижегородской области за 9 лет наблюдения (1998–2007
гг.).
Всероссийская
конференция
ОССН:
«Сердечная
недостаточность, 2007 год» – М., 2007. – с. 38.
7. Фомин И. В., Бадин Ю. В., Егорова И. С., Щербинина Е. В.
Гендерные различия в распространенности сердечно-сосудистых
заболеваний
(данные
когортного
исследования
репрезентативной выборки Нижегородской области 1998–2002
гг.). Проблемы женского здоровья. 2006;1 (1):37–40
8. McAlister F.A., Teo K.K., Taher M. et al. Insights into the
contemporary epidemiology and outpatient management of
congestive heart failure. Am Heart J. 1999; 138 (1 Pt 1):87–94.

9. Терещенко С.Н., Жиров И.В., Нарусов О.Ю., Мареев Ю.В.,
Затейщиков Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко
А.Н., Насонова С.Н., Стукалова О.В., Саидова М.А., Скворцов А.А.,
Шария М.А., Явелов И.С. Диагностика и лечение хронической и
острой сердечной недостаточности. Кардиологический вестник,
2016; № 2:3-33
10. McMurray J. Clinical practice. Systolic heart failure. N Engl J
Med. 2010; 362 (3):228–238
11. Chen J., Normand S.L., Wang Y., Krumholz H.M. National and
regional trends in heart failure hospitalization and mortality rates for
Medicare beneﬁciaries, 1998–2008. JAMA. 2011; 306 (15):1669–1678
12. Dunlay S.M., Redﬁeld M.M., Weston S.A. et al. Hospitalizations
after heart failure diagnosis a community perspective. J Am Coll
Cardiol. 2009; 54 (18):1695–1702.
13. Hogg K., Swedberg K., McMurray J. Heart Failure with
preserved left ventricular systolic function. Epidemiology, Clinical
Characteristics, and Prognosis. J Am Coll Cardiol. 2004;43 (3):317–
327.
14. Агеев Ф.Т. Влияние современных медикаментозных
средств на течение заболевания «качество жизни» и прогноз
больных с различными стадиями хронической сердечной
недостаточности. Автореф. Дисс. Докт., Москва, 1997.
15. Senni M., Gavazzi A., Oliva F., at al. In-hospital and 1-year
outcomes of acute heart failure patients according to presentation (de
novo vs. worsening) and ejection fraction. Results from IN-HF
Outcome Registry. Intern J Cardiol 2014;173: 163-9.
16. Cowie M.R., Fox K.F., Wood D.A. et al. Hospitalization of
patients with heart failure: a population-based study. Eur Heart J.
2002; 23 (11):877–885.
17. Беленков Ю.Н., Овчинников А.Г., Агеев Ф.Т., Сербул В.М.
Гипертрофия левого желудочка: роль ренин-ангиотензиновой
системы. Кардиоваскулярная терапия и профилактика 2008;
№2:98-108.
18. Овчинников А.Г., Агеев Ф.Т., Свирида О.Н.
Патогенетический подход к терапии пациентов с хронической
сердечной недостаточностью и сохраненной систолической

функцией левого желудочка. Кардиологический вестник 2011;
№1: 33-39.
19. Pocock S.J., Wang D., Pfeffer M.A. et al. Predictors of mortality
and morbidity in patients with chronic heart failure. Eur Heart J. 2006;
27 (1):65–75.
20. Komajda M., Carson P.E., Hetzel S. et al. Factors associated
with outcome in heart failure with preserved ejection fraction:
ﬁndings from the Irbesartan in Heart Failure with Preserved Ejection
Fraction Study (I-PRESERVE). Circ Heart Fail. 2011; 4 (1):27–35.
21. Ketchum E.S., Levy W.C. Establishing prognosis in heart
failure: a multimarker approach. Prog Cardiovasc Dis. 2011; 54 (2):86–
96.
22. Ho K.K., Anderson K.M., Kannel W.B. et al. Survival after the
onset of congestive heart failure in Framingham Heart Study
subjects.Circulation. 1993; 88 (1):107–115.
23. Даниелян М. О. Прогноз и лечение хронической сердечной
недостаточности (данные 20-и летнего наблюдения). Автореф.
дис. канд. мед.наук. Москва. 2001
24. Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в
когортной выборке Нижегородской области (данные 1998–2002
годов.). Всероссийская конференция ОССН: «Сердечная
недостаточность, 2005 год» – М., 2005. – с. 31–32
25. Якушин С.С., Смирнова Е.А., Лиферов Р.А. Выживаемость
больных хронической сердечной недостаточностью (данные
когортного исследования репрезентативной выборки населения
Рязанской области)// Сердечная недостаточность. 2011; 12 (4):218-
221.
26. Wedel H., McMurrayJ.J., LindbergMetal. Predictors of fatal and
non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial
in Heart Failure (CORONA): incremental value of apolipoprotein A-1,
high-sensitivity C-reactive peptide and N-terminal proB-type
natriuretic peptide. Eur J Heart Fail. 2009; 11 (3):281–291
27. Allen L.A., Felker G.M., Pocock S. et al. Liver function
abnormalities and outcome in patients with chronic heart failure: data
from the Candesartan in Heart Failure: Assessment of Reduction in

Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009; 11
(2):170–177.
28. Jackson C.E., Solomon S.D., Gerstein H.C. et al. Albuminuria in
chronic heart failure: prevalence and prognostic importance. Lancet
2009; 374 (9689):543–550.
29. Felker G.M., Allen L.A., Pocock S.J. et al. Red cell distribution
width as a novel prognostic marker in heart failure: data from the
CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;
50(1):40–47.
30. Беленков Ю. Н., Фомин И. В., Мареев В. Ю. и др. Первые
результаты Российского эпидемиологического исследования
31. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю. и др. Больные с
хронической сердечной недостаточностью в российской
амбулаторной практике: особенности контингента, диагностики
и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал
Сердечная Недостаточность 2004;5 (1):4–7.
32. Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др.
Распространенность хронической сердечной недостаточности в
Европейской части Российской Федерации – данные ЭПОХА–
ХСН. Журнал Сердечная Недостаточность 2006;7 (1): 112–115.
33. Davie P., Francis C.M., Caruana L., Sutherland G.R., McMurray
J.J. Assessing diagnosis in heart failure: which features are any use?
QJM 1997; 90: 335–339
34. Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P.,
Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M.,
Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual
patient data meta-analysis of diagnosis of heart failure, with
modelling of implications of different diagnostic strategies in primary
care. Health Technol Assess 2009; 13:1–207
35. Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E.,
Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation
of geriatric outpatients with suspected heart failure: value of
symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13:518–
527
36. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail
Rev 2006; 11:95–107;

37. Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R.,
Mosterd A., Moons KGM, Lammers J.W., Cowie M.R., Grobbee D.E.,
Hoes A.W. The diagnostic value of physical examination and
additional testing in primary care patients with suspected heart
failure. Circulation 2011;124: 2865–2873
38. Weingärtner O, Hasan T, Böhm M.Pathophysiology and
differential diagnosis of dyspnea Herz. 2004 Sep; 29(6):595-601. doi:
10.1007/s00059-004-2594-0.
39. Fries R.Differential diagnosis of leg edema. MMW Fortschr
Med. 2004 Apr 15; 146(16):39-4.
40. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J,
Fonarow GC, et al. Forecasting the impact of heart failure in the
United States: a policy statement from the American Heart
Association. Circ Heart Fail. 2013 May; 6(3):606-19. doi:
10.1161/HHF.0b013e318291329a
41. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL,
Cannon CP, et al. Trends in patients hospitalized with heart failure
and preserved left ventricular ejection fraction: prevalence, therapies,
and outcomes. Circulation. 2012 Jul 3; 126(1):65-75. doi:
10.1161/CIRCULATIONAHA.111.080770.
42. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et
al. Relation of disease pathogenesis and risk factors to heart failure
with preserved or reduced ejection fraction: insights from the
Framingham heart study of the national heart, lung, and blood
institute. Circulation. 2009 Jun 23; 119(24):3070-7. doi:
10.1161/CIRCULATIONAHA.108.815944
43. Ощепкова Е.В., Лазарева Н.В., Сатлыкова Д.Ф., Терещенко
С.Н. Первые результаты Российского регистра хронической
сердечной недостаточности. Кардиология 2015. Т. 55. № 5. С. 22-
28.
44. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with
preserved ejection fraction: Comorbidities drive myocardial
dysfunction and remodeling through coronary microvascular
endothelial inﬂammation. J Am Coll Cardiol 2013 Jul 23; 62(4):263-71.
doi: 10.1016/j.jacc.2013.02.092.
45. Redﬁeld MM. Heart Failure with Preserved Ejection Fraction. N
Engl J Med. 2017 Mar 2; 376(9):897. doi: 10.1056/NEJMc1615918.

46. Paulus WJ, Dal Canto E. Distinct Myocardial Targets for
Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection
Fraction.
JACC
Heart
Fail
2018
Jan;6(1):1-7.
doi:
10.1016/j.jchf.2017.07.012.
47. Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A,
Chaanine AH, Agarwal SK. Epidemiology of heart failure with
preserved ejection fraction. Curr Heart Fail Rep 2014 Dec; 11(4):354-
65. doi: 10.1007/s11897-014-0223-7.
48. Liu M, Fang F, Yu CM. Noncardiac Comorbidities in Heart
Failure With Preserved Ejection Fraction—A Commonly Ignored Fact.
Circ J 2015; 79(5):954-9. doi: 10.1253/circj.CJ-15-0056.
49. Dunlay SM, Roger VL, Redﬁeld MM. Epidemiology of heart
failure with preserved ejection fraction. Nat Rev Cardiol. 2017 Oct;
14(10):591-602. doi: 10.1038/nrcardio.2017.65.
50. Roberts E., Ludman A.J., Dworzynski K., Al-Mohammad A.,
Cowie M.R., McMurray J.J.V., Mant J. The diagnostic accuracy of the
natriuretic peptides in heart failure: systematic review and diagnostic
meta-analysis in the acute care setting. BMJ 2015; 350:h910.
51. Zaphiriou A., Robb S., Murray-Thomas T., Mendez G., Fox K.,
McDonagh T., Hardman S.M.C., Dargie H.J., Cowie M.R. The
diagnostic accuracy of plasma BNP and NTpro мозговой
натрийуретический пептид in patients referred from primary care
with suspected heart failure: results of the UK natriuretic peptide
study. Eur J Heart Fail 2005; 7:537–541.
52. Fuat A., Murphy J.J., Hungin A.P.S., Curry J., Mehrzad A.A.,
Hetherington A., Johnston J.I., Smellie W.S.A., Duffy V., Cawley P. The
diagnostic accuracy and utility of a B-type natriuretic peptide test in a
community population of patients with suspected heart failure. Br J
Gen Pract 2006; 56:327–333.
53. Yamamoto K., Burnett J.C., Bermudez E.A., Jougasaki M., Bailey
K.R., Redﬁeld M.M. Clinical criteria and biochemical markers for the
detection of systolic dysfunction. J Card Fail 2000; 6:194–200.
54. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson
S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in
assessment of patients with possible new heart failure in primary
care. Lancet 1997; 350:1349–1353.

55. Krishnaswamy P., Lubien E., Clopton P., Koon J., Kazanegra R.,
Wanner E., Gardetto N., Garcia A., DeMaria A., Maisel A.S. Utility of
B-natriuretic peptide levels in identifying patients with left
ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:
274–279.
56. Kelder J.C., Cramer M.J., Verweij W.M., Grobbee D.E., Hoes
A.W.Clinical utility of three B-type natriuretic peptide assays for the
initial diagnostic assessment of new slow-onset heart failure.
JCardFail 2011; 17: 729–734.
57. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P,
Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type
peptide predicts treatment outcomes in patients admitted for
decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;
37:386–391.
58. McCullough PA, Duc P, Omland T, McCord J, Nowak RM,
Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW,
Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P,
Krishnaswamy P, Kazanegra R, Maisel AS; Breathing Not Properly
Multinational Study Investigators. B-type natriuretic peptide and
renal function in the diagnosis of heart failure: an analysis from the
breathing not properly multinational study. Am J Kidney Dis 2003;41:
571–579.
59. Jankowska EA , von Haehling S, Anker SD, Macdougall IC,
Ponikowski P. Iron deﬁciency and heart failure: diagnostic dilemmas
and therapeutic perspectives. Eur Heart J 2013; 34:816–826.
60. Jankowska EA , Malyszko J, Ardehali H, Koc-Zorawska E,
Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJV,
Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with
chronic heart failure. Eur Heart J 2013; 34:827–834
61. Damman K , Valente MAE, Voors AA, O"Connor CM, van
Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal
function, and outcome in patients with heart failure: an updated
meta-analysis. Eur Heart J 2014; 35:455–469.
62. Filippatos G, Farmakis D, Parissis J. Renal dysfunction and
heart failure: things are seldom what they seem. Eur Heart J 2014;
35:416–418;

63. Desai AS. Hyperkalemia in patients with heart failure:
incidence, prevalence, and management. Curr Heart Fail Rep 2009;
6:272–280.
64. Aguilar D , Bozkurt B, Ramasubbu K, Deswal A. Relationship of
hemoglobin A1C and mortality in heart failure patients with diabetes.
J Am Coll Cardiol 2009; 54:422–428.
65. Ewid M., Sherif H., Allihimy A.S. et al. AST/ALT ratio predicts
the functional severity of chronic heart failure with reduced left
ventricular ejection fraction. BMC Res Notes. 2020; 13: 178. doi:
10.1186/s13104-020-05031-3.
66. Wannamethee S.G., Whincup P.H., Shaper A.G. Γ-
glutamyltransferase, hepatic enzymes, and risk of incident heart
failure in older men. Arterioscler Thromb Vasc Biol. 2012.
67. Poelzl G., Eberl C., Achrainer H. et al. Prevalence and
prognostic signiﬁcance of elevated gamma-glutamyltransferase in
chronic heart failure. Circ Heart Fail. 2009.
68. Ess M., Christine Mussner-Seeber K., Siegfried Mariacher S. et
al. γ-Glutamyltransferase rather than total bilirubin predicts outcome
in chronic heart failure.J Card Fail. 2011.
69. Yamazoe M., Mizuno A., Nishi Y., Niwa K., Isobeet M. Serum
alkaline phosphatase as a predictor of worsening renal function in
patients with acute decompensated heart failure.J Cardiol. 2016.
70. Shamban L., Patela B., Williamsaet M. et al. Signiﬁcantly
Elevated Liver Alkaline Phosphatase in Congestive Heart Failure.
Gastroenterology Res. 2014.
71. Rhee C.M., Curhan G.C., Alexander E.R. et al. Subclinical
Hypothyroidism and Survival: The Effects of Heart Failure and Race J
Clin Endocrinol Metab . 2013 Jun; 98(6):2326-36. doi:
10.1210/jc.2013-1039.
72. Pingitore A., Landi P., Taddei M.C. et al. Triiodothyronine
levels for risk stratiﬁcation of patients with chronic heart failure. Am J
Med. 2005; 118:132–136. doi: 10.1016/j.amjmed.2004.07.052.
73. Passino C., Pingitore A., Landi P. et al. Prognostic value of
combined measurement of brain natriuretic peptide and
triiodothyronine in heart failure.J Card Fail. 2009; 15:35–40. doi:
10.1016/j.cardfail.2008.08.008.

74. Felipe Martinez. Thyroid hormones and heart failure. Heart
Failure Reviews volume 21, pages361–364(2016).
75. Rauchhaus M, Clark AL, Doehner W et al. The relationship
between cholesterol and survival in patients with chronic heart
failure. J Am CollCardiol, 2003, 2(11): 1933-1940
76. Cappola A.R., Fried L.P., Arnold A.M. at al. Thyroid status,
cardiovascular risk, and mortality in older adults. JAMA. 2006;
295:1033–1041. doi: 10.1001/jama.295.9.1033
77. Greene SJ, Vaduganathan M, Lupi L et al. Prog nostic
signiﬁcance of serum total cholesterol and triglyceride levels in
patients hospitalized for heart failure with reduced ejection fraction
(from the EVEREST Trial). Am J Cardiol, 2013, 111(4): 574-81.
78. Khunti K, Squire I, Abrams KR, Sutton AJ.Accuracy of a 12-lead
electrocardiogram in screening patients with suspected heart failure
for open access echocardiography: a systematic review and meta-
analysis. Eur J Heart Fail. 2004 Aug;6(5):571-6. doi:
10.1016/j.ejheart.2004.03.013.
79. Davie A.P., Francis C.M., Love M.P., Caruana L., Starkey I.R.,
Shaw T.R., Sutherland G.R., McMurray J.J. Value of the
electrocardiogram in identifying heart failure due to left ventricular
systolic dysfunction. BMJ 1996; 312:222.
80. Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K.,
Parrillo J.E., Calvin J.E. Utility of history, physical examination,
electrocardiogram, and chest radiograph for differentiating normal
from decreased systolic function in patients with heart failure.Am J
Med 2002;112:437–445.
81. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of
echocardiography in patients hospitalized for heart failure: a
prospective observational study. Arch Cardiovasc Dis. 2008; 101: 465–
473.
82. Kirkpatrick JN, Vannan MA, Narula J, Lang RM.
Echocardiography in heart failure: applications, utility, and new
horizons. JAm Coll Cardiol. 2007; 50:381–396.
83. Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of
echocardiography in the management of congestive heart failure in
the community. J Am Coll Cardiol. 1999; 33:164–170.

84. Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography
and risk prediction in advanced heart failure: incremental value over
clinical markers. J Card Fail. 2009; 15: 586–592.
85. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP
3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O"Gara PT, Rigolin VH,
Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the
2014 AHA/ACC Guideline for the Management of Patients With
Valvular Heart Disease: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. J Am Coll Cardiol. 2017 Jul 11;70(2):252-289. doi:
10.1016/j.jacc.2017.03.011
86. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie
M, et al. Expert consensus for multimodality imaging evaluation of
adult patients during and after cancer therapy: a report from the
American Society of Echocardiography and the European Association
of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep;
27(9):911-39. doi: 10.1016/j.echo.2014.07.012.
87. Porter TR, Shillcutt SK, Adams MS, Desjardins G, Glas KE,
Olson JJ, Troughton RW. Guidelines for the use of echocardiography as
a monitor for therapeutic intervention in adults: a report from the
American Society of Echocardiography. J Am Soc Echocardiogr. 2015
Jan; 28(1):40-56. doi: 10.1016/j.echo.2014.09.009.
88. EchoNoRMAL (Echocardiographic Normal Ranges Meta-
Analysis of the Left Heart) Collaboration. Ethnic-Speciﬁc Normative
Reference Values for Echocardiographic LA and LV Size, LV Mass, and
Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging
2015;8: 656-65.
89. Muraru D,Badano LP, Peluso D, Dal Bianco L, Casablanca S,
Kocabay G, et al. Comprehensive analysis of left ventricular geometry
and function by three-dimensional echocardiography in healthy
adults. J Am Soc Echocardiogr 2013;26: 618-28.
90. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C,
Kacharava G, et al. Echocardiographic reference ranges for normal
cardiac chamber size: results from the NORRE study. Eur Heart J
Cardiovasc Imaging 2014;15:680-90.
91. Alherbish, A., Becher, H., Alemayehu, W., Paterson, D. I.,
Butler, C. R., Anderson, T. J. (2018). Impact of contrast
echocardiography on accurate discrimination of speciﬁc degree of left

ventricular systolic dysfunction and comparison with cardiac
magnetic
resonance
imaging.
Echocardiography.
doi:10.1111/echo.14152
92. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE.
Performance of 3-dimensional echocardiography in measuring left
ventricular volumes and ejection fraction: a systematic review and
meta-analysis. J Am Coll Cardiol 2012;59: 1799-808.
93. Goldenberg I., Moss A.J., Hall W.J., et al. Predictors of response
to cardiac resynchronization therapy in the Multicenter Automatic
Deﬁbrillator Implantation Trial with Cardiac Resynchronization
Therapy (MADIT-CRT). Circulation 2011; 124 (14):1527-1536
94. Thavendiranathan P., Liu S., Datta S., et al. Automated
quantiﬁcation of mitral inﬂow and aortic outﬂow stroke volumes by
three-dimensional real-time volume color-ﬂow Doppler transthoracic
echocardiography: comparison with pulsed-wave Doppler and cardiac
magnetic resonance imaging. J Am Soc Echocardiogr 2012; 25 (1):56-
65.
95. Hoffmann R, von Bardeleben S, ten Cate F, et al. Assessment of
systolic left ventricular function: a multi-centre comparison of
cineventriculography, cardiac magnetic resonance imaging,
unenhanced and contrast-enhanced echocardiography. Eur Heart J
2005 Mar; 26(6):607-16.
96. Hoffmann R, Barletta G, von Bardeleben S, Vanoverschelde JL,
Kasprzak J, Greis C, et al. Analysis of left ventricular volumes and
function—a multicenter comparison of cineventriculography, cardiac
magnetic resonance imaging, unenhanced and contrast enhanced 2D
and 3D echocardiography. J Am Soc Echocardiogr 2014; 27:292-301
97. Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A.,
Marwick T.H., Use of Myocardial Strain Imaging by Echocardiography
for the Early Detection of Cardiotoxicity in Patients During and After
Cancer Chemotherapy: A Systematic Review. J Am Coll Cardiol 2014;
63:2751–2768
98. Mignot A, Donal E, Zaroui A, Reant P, Salem A, Hamon C, et al.
Global longitudinal strain as a major predictor of cardiac events in
patients with depressed left ventricular function: a multicenter study.
J Am Soc Echocardiogr 2010; 23: 1019-24.

99. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH.
Normal ranges of left ventricular strain: a meta-analysis. J Am Soc
Echocardiogr 2013; 26:185-91.
100. T. Stanton, R. Leano, T.H. Marwick: Prediction of all-cause
mortality from global longitudinal speckle strain: comparison with
ejection fraction and wall motion scoring. Circ Cardiovasc Imaging
2009;2 (5):356-364.
101. M. Bansal, G.Y. Cho, J. Chan, et al. Feasibility and accuracy of
different techniques of two-dimensional speckle based strain and
validation with harmonic phase magnetic resonance imaging. J Am
Soc Echocardiogr 2008; 21:1318-1325
102. Nagueh S., Smiseth O., Appleton C., et al. Recommendations
for the evaluation of left ventricular diastolic function by
echocardiography: an update from the American Society of
Echocardiography and the European Association of Cardiovascular
Imaging. J Am Soc Echocardiogr 2016; 29:277-314
103. Hawkins N.M., Petrie M.C., Jhund P.S., ChalmersG.W., Dunn
F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary
disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail
2009;11:130–139.
104. Jolicœur EM, Dunning A, Castelvecchio S, Dabrowski R,
Waclawiw MA, Petrie MC, Stewart R, Jhund PS, Desvigne-Nickens P,
Panza JA, Bonow RO, Sun B, San TR, Al-Khalidi HR, Rouleau JL,
Velazquez EJ, Cleland JGF. Importance of angina in patients with
coronary disease, heart failure, and left ventricular systolic
dysfunction: insights from STICH. J Am Coll Cardiol 2015;66:2092–
2100.
105. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer
M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN,
MacCarthy PA, Fearon WF, Investigators FS. Fractional ﬂow reserve
vs. angiography for guiding percutaneous coronary intervention. N
Engl J Med 2009;360(3):213 – 224
106. Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di
Seraﬁno L, Van Praet F, Van Mieghem C, Stockman B, Wijns W,
Degrieck I, Barbato E. Fractional ﬂow reserve-guided vs. angiography-
guided coronary artery bypass graft surgery. Circu- lation
2013;128(13):1405 – 1411.

107. Beller GA, Heede RC. SPECT imaging for detecting coronary
artery disease and determining prognosis by noninvasive assessment
of myocardial perfusion and myocardial viability. J Cardiovasc Transl
Res 2011;4:416–424.
108. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N,
Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD,
Benard F, Lamy A, Iwanochko RM. F-18-ﬂuorodeoxyglucose positron
emission tomography imaging-assisted management of patients with
severe left ventricular dysfunction and suspected coronary disease: a
randomized, controlled trial (PARR-2). J Am Coll Cardiol
2007;50:2002–2012.
109. Gonza´lez-Lo´pez E, Gallego-Delgado M, Guzzo-Merello G, de
Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C,
Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type
transthyretin amyloidosis as a cause of heart failure with preserved
ejection fraction. Eur Heart J 2015;36:2585–2594.
110. S. Longhi, P.L. Guidalotti, C.C. Quarta, et al. Identiﬁcation of
TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. J
Am Coll Cardiol Img, 7 (2014), pp. 531-532
111. S. Bokhari, A. Castaño, T. Pozniakoff, et al. 99mTc-
pyrophosphate scintigraphy for differentiating light-chain cardiac
amyloidosis from the transthyretin-related familial and senile cardiac
amyloidosis. Circ Cardiovasc Imaging, 6 (2013), pp. 195-201
112. W.A. Aljaroudi, M.Y. Desai, W.H. Tang, et al. Role of imaging in
the diagnosis and management of patients with cardiac amyloidosis:
state of the art review and focus on emerging nuclear techniques. J
Nucl Cardiol, 21 (2014), pp. 271-283.
113. Saric M, Armour AC, Arnaout MS, Chaudhry FA, Grimm RA,
Kronzon I, et al. Guidelines for the Use of Echocardiography in the
Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr.
2016 Jan;29(1):1-42. doi: 10.1016/j.echo.2015.09.011.
114. Douglas PS, Garcia MJ, Haines DE, et al.
ACCF/ASE/AHA/ASNC/HFSA/HRS/ SCAI/SCCM/SCCT/SCMR 2011
appropriate use criteria for echocardiography. J Am Coll Cardiol.
2011;57:1126–1166

115. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA
guideline for the management of heart failure: a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol.
2013;62:e147–e239
116. Abhishek Khemka , Stephen G Sawada Dobutamine
echocardiography for assessment of viability in the current era. Curr
Opin
Cardiol
.
2019
Sep;34(5):484-489.
doi:
10.1097/HCO.0000000000000658.
117. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC,
Cerqueira MD, Hachamovitch R. Identiﬁcation of therapeutic beneﬁt
from revascularization in patients with left ventricular systolic
dysfunction inducible ischemia versus hibernating myocardium. Circ
Cardiovasc Imaging 2013;6:363–372.
118. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-
Nickens P, et al. Myocardial viability and survival in ischemic left
ventricular dysfunction. N Engl J Med 2011;364:1617–1625.
119. deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW,
Eichhorn EJ, et al. Usefulness of dobutamine echocardiography in
distinguishing severe from nonsevere valvular aortic stenosis in
patients with depressed left ventricular function and low transvalvular
gradients. Am J Cardiol 1995;75:191-4
120. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H,
Baleynaud S, et al. Outcome after aortic valve replacement for low-
ﬂow/low-gradient aortic stenosis without contractile reserve on
dobutamine stress echocardiography. J Am Coll Cardiol 2009;53:1865-
73
121. Clavel MA, Fuchs C, Burwash IG, Mundigler G, Dumesnil JG,
Baumgartner H, et al. Predictors of outcomes in low-ﬂow, low-
gradient aortic stenosis: results of the multicenter TOPAS Study.
Circulation 2008;118(14 Suppl):S234-42.
122. Garnier F, Eicher J-C, Jazayeri S, Bertaux G, Bouchot O, Aho L-
S, Wolf J-E, Laurent G. Usefulness and limitations of contractile
reserve evaluation in patients with low-ﬂow, low-gradient aortic
stenosis eligible for cardiac resynchronization therapy. Eur J Heart
Fail 2014;16:648–654.

123. Erdei T, Smiseth OA, Marino P, Fraser AG. A systematic review
of diastolic stress tests in heart failure with preserved ejection
fraction, with proposals from the EU-FP7 MEDIA study group. Eur J
Heart Fail 2014;16:1345–1361.
124. Donal E, Lund LH, Oger E, Reynaud A, Schnell F, Persson H, et
al. Value of exercise echocardiography in heart failure with preserved
ejection fraction: a substudy from the KaRen study. Eur Heart J
Cardiovasc Imaging 2016;17:106–113
125. Borlaug B., Nishimura R., Sorajja P., et al. Exercise
hemodynamics enhance diagnosis of early heart failure with
preserved ejection fraction. Circ Heart Fail 2010;3:588―95
126. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J,
Halamert E, Scherer M, Bellinger R, Martin A, Benton R, Delago A,
Min JK. Diagnostic performance of 64-multidetector row coronary
computed tomographic angiography for evaluation of coronary artery
stenosis in individuals without known coronary artery disease: results
from the prospective multicenter ACCURACY (Assessment by
Coronary Computed Tomographic Angiography of Individuals
Undergoing Invasive Coronary Angiography) trial, J Am Coll Cardiol ,
2008, vol. 52 (pg. 1724-1732).
127. Paech DC, Weston AR. A systematic review of the clinical
effectiveness of 64-slice or higher computed tomography angiography
as an alternative to invasive coronary angiography in the
investigation of suspected coronary artery disease, BMC Cardiovasc
Disord , 2011, vol. 11 pg. 32
128. Goldstein JA Gallagher MJ O"Neill WW Ross MA O"Neil BJ Raff
GL . A randomized controlled trial of multi-slice coronary computed
tomography for evaluation of acute chest pain. J Am Coll Cardiol
2007;49:863–871.
129. Hoffmann U Truong QA Schoenfeld DA Chou ET Woodard PK
Nagurney JT Pope JH Hauser TH White CS Weiner SG Kalanjian S
Mullins ME Mikati I Peacock WF Zakroysky P Hayden D Goehler A Lee
H Gazelle GS Wiviott SD Fleg JL Udelson JE . Coronary CT
angiography versus standard evaluation in acute chest pain. N Engl J
Med 2012;367:299–308.
130. Windecker S., Kolh P., Alfonso F., Collet J-P., Cremer J., Falk. V,
Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A.,
Knuuti J., Landmesser U., Laufer G., Neumann F-J., Richter D.J.,

Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L.,
Valgimigli M., Wijns W. 2014 ESC/EACTS Guidelines on myocardial
revascularization: the Task Force on Myocardial Revascularization of
the European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS). Developed with the
special contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–
2619.
131. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden
C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira
J.R., Gersh B.J., Gitt A.K., Hulot J-S., Marx N., Opie L.H., Pﬁsterer M.,
Prescott E., Ruschitzka F., Sabate´ M., Senior R., Taggart D.P., van der
Wall E.E., Vrints C.J.M., Zamorano J.L.,Baumgartner H., Bax J.J.,
Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D.,
Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P.,Linhart A.,
Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo
J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Valgimigli
M.,Claeys M.J., Donner-Banzhoff N., Frank H., Funck-Brentano C.,
Gaemperli O., Gonzalez-Juanatey J.R., Hamilos M., Husted S., James
S.K., Kervinen K.,Kristensen S.D., Maggioni A. Pietro, Pries A.R.,
Romeo F., Ryde´n L., Simoons M.L., Steg P.G., Timmis A., Yildirir A.
2013 ESC guidelines on the management of stable coronary artery
disease. Eur Heart J 2013;34:2949–3003.
132. Rofﬁ M., Patrono C., Collet J-P., Mueller C., Valgimigli M.,
Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B.,
Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J.,
Mukherjee D., Storey R.F., Windecker S. 2015 ESC Guidelines for the
management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation. Eur Heart J 2015; ehv320
133. Sousa PA, Bettencourt N, Dias Ferreira N, Carvalho M, Leite D,
Ferreira W, de Jesus I, Gama V. Role of cardiac multidetector
computed tomography in the exclusion of ischemic etiology in heart
failure patients. Rev Port Cardiol. 2014 Oct;33(10):629-36
134. Hundle WG, Blumke D, Bogaert JG, et al. Society for
cardiovascular magnetic resonance guidelines for reporting
cardiovascular magnetic resonance examinations. J Cardiovasc Magn
reson 2009; 11:5

135. Kramer C, Barkhausen J, Flamn SD, et al. Standardised
cardiovascular magnetic resonance imaging (CMR) protocols, society
for cardiovascular magnetic resonance: board of trustees task force on
standardized protocols. J Cardiovasc Magn Reson, 2008; 10:35
136. Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of
cardiac magnetic resonance analysis of regional and diffuse
interstitial myocardial ﬁbrosis. European heart journal cardiovascular
Imaging. 2015; 16:14–22.
137. Gulati A, Jabbour A, Ismail TF, et al. Association of ﬁbrosis with
mortality and sudden cardiac death in patients with nonischemic
dilated cardiomyopathy. JAMA. 2013; 309:896–908.
138. Puntmann VO, Carr-White G, Jabbour A, et al. T1-Mapping and
Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and
Heart Failure. JACC Cardiovascular imaging. 2016; 9:40–50.
139. Kalb B, Indik JH, Ott P, Martin DR.MRI of patients with
implanted cardiac devices. J Magn Reson Imaging. 2018
Mar;47(3):595-603. doi: 10.1002
140. Weidman EK, Dean KE, Rivera W, Loftus ML, Stokes TW, Min
RJ. MRI safety: a report of current practice and advancements in
patient preparation and screening. Clin Imaging. 2015 Nov-
Dec;39(6):935-7. doi: 10.1016.
141. Tsai LL, Grant AK, Mortele KJ, Kung JW, Smith MP. A Practical
Guide to MR Imaging Safety: What Radiologists Need to Know.
Radiographics. 2015 Oct;35(6):1722-37. doi: 10.1148
142. Sechtem U, Pﬂugfelder P, Higgins CB. Quantiﬁcation of cardiac
function by conventional and cine magnetic resonance imaging.
Cardiovasc Intervent Radiol 1987; 10: 365– 373
143. Pattynama PM, Lamb HJ, van der Velde EA, van der Wall EE, de
Roos A. Left ventricular measurements with cine and spin
‐echo MRI
imaging: a study of reproducibility with variance component analysis.
Radiology 1993; 187: 261– 268.
144. Reichek N. Magnetic resonance imaging for assessment of
myocardial function. Magn Reson Q1991; 7: 255–274.
145. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer
S. Normal human left and right ventricular and left atrial dimensions
using steady state free precession magnetic resonance imaging. J

Cardiovasc Magn Reson. 2005; 7: 775– 782
146. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left
ventricular systolic and diastolic function by steady state free
precession cardiovascular magnetic resonance. J Cardiovasc Magn
Reson 2006; 8: 417– 426.
147. Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right
ventricular systolic and diastolic function normalized to age, gender
and body surface area from steady
‐state free precession cardiovascular
magnetic resonance. Eur Heart J 2006; 27: 2879–2888.
148. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA,
Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ,
Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, Harrington
RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA,
Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR,
Moliterno DJ, Mukherjee D, Rosenson RS, Schoﬁeld RS, Shubrooks SJ,
Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/
ACR/AHA/NASCI/SCMR 2010 expert consensus document on
cardiovascular magnetic resonance: a report of the american college
of cardiology foundation task force on expert consensus documents.
Circulation 2010;121:2462–2508.
149. Valsangiocomo Buechel ER, Mertens L. Imaging the right heart:
the use of integrated multimodality imaging. Eur Heart J 2012; 33:
949–960
150. Grothues F, Moon J, Bellenger N, Smith G, Klein H, Pennell D.
Interstudy reproducibility of right ventricular volumes, function, and
mass with cardiovascular magnetic resonance. Am Heart J
2004;147:218–223
151. Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J,
Webb GD. Recommendations for cardiovascular magnetic resonance
in adults with congenital heart disease from the respective working
groups of the European Society of Cardiology. Eur Heart J
2010;31:794–805
152. Gonzalez JA, Kramer CM. Role of imaging techniques for
diagnosis, prognosis and management of heart failure patients:
cardiac magnetic resonance. Curr Heart Fail Rep 2015;12:276–283

153. G. Pons-Llado, F. Carreras, X. Borras, J. Palmer, J. Llauger, A.
Bayes de Luna Comparison of morphologic assessment of
hypertrophic cardiomyopathy by magnetic resonance versus
echocardiographic imaging. Am J Cardiol, 79 (1997), pp. 1651-1656.
154. J.C. Moon, N.G. Fisher, W.J. McKenna, D.J. Pennell Detection of
apical hypertrophic cardiomyopathy by cardiovascular magnetic
resonance in patients with non-diagnostic echocardiography. Heart,
90 (2004), pp. 645-649.
155. R. Fattori, E. Biagini, M. Lorenzini, K. Buttazzi, L. Lovato, C.
Rapezzi. Signiﬁcance of magnetic resonance imaging in apical
hypertrophic cardiomyopathy. Am J Cardiol, 105 (2010), pp. 1592-159.
156. Ashrith G, Gupta D, Hanmer J, Weiss RM. Cardiovascular
magnetic resonance characterization of left ventricular non-
compaction provides independent prognostic information in patients
with incident heart failure or suspected cardiomyopathy. J Cardiovasc
Magn Reson 2014;16:64.
157. Choi Y, Kim SM, Lee SC, Chang SA, Jang SY, Choe YH.
Quantiﬁcation of left ventricular trabeculae using cardiovascular
magnetic resonance for the diagnosis of left ventricular non-
compaction: evaluation of trabecular volume and reﬁned semi-
quantitative criteria. J Cardiovasc Magn Reson 2016;18:24.
158. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed
enhancement cardiovascular magnetic resonance assessment of non-
ischaemic cardiomyopathies. Eur Heart J 2005;26:1461–1474
159. Yoshida A., Ishibashi-Ueda H., Yamada N., Kanzaki H.,
Hasegawa T., Takahama H.,Amaki M., Asakura M., Kitakaze M. Direct
comparison of the diagnostic capability of cardiac magnetic resonance
and endomyocardial biopsy in patients with heart failure.
EurJHeartFail 2013;15:166–175.
160. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD,
Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S,
Schulz-Menger J, Schelbert EB. Myocardial T1 mapping and
extracellular volume quantiﬁcation: a Society for Cardiovascular
Magnetic Resonance (SCMR) and CMR Working Group of the
European Society of Cardiology consensus statement. J Cardiovasc
Magn Reson 2013;15:92

161. Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular
magnetic resonance on management and clinical decision-making in
heart failure patients. Journal of cardiovascular magnetic resonance:
ofﬁcial journal of the Society for Cardiovascular Magnetic Resonance.
2013;15:89.
162. Sobol, E. Horn, A. Dele-Michael et al. Assessment of
unexplained cardiomyopathy: clinical utility of delayed enhancement
cardiac magnetic resonance compared to endomyocardial biopsy.
Journal of the American College of Cardiology. 2012 vol. 59, no. 13, p.
E1553, 2012.
163. Theodoros D.KaramitsosMD, Christos A.Papanastasiou,
Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis:
The Best Way Forward. JACC Cardiovasc Imaging. 2019; 8: S1936-
878X
164. Vogelsberg H., Mahrholdt H., Deluigi C.C. et al. Cardiovascular
magnetic resonance in clinically suspected cardiac amyloidosis:
noninvasive imaging compared to endomyocardial biopsy. J. Am. Coll.
Cardiol. 2008;51:1022–1030
165. Nam BD, Kim SM, Jung HN, et al. Comparison of quantitative
imaging parameters using cardiovascular magnetic resonance
between cardiac amyloidosis and hypertrophic cardiomyopathy:
inversion time scout versus T1 mapping. Int J Cardiovasc Imaging.
2018;34(11):1769–77
166. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late
Gadolinium Enhancement Cardiovascular Magnetic Resonance in
Cardiac Amyloidosis. Circulation. 2015; 132:1570–9. [PubMed:
26362631]
167. Karur GR, Robison S, Iwanochko RM, et al. Use of myocardial
T1 mapping at 3.0 T to differentiate Anderson-Fabry disease from
hypertrophic cardiomyopathy. Radiology. 2018;288(2):398–406
168. Sado DM, White SK, Piechnik SK, et al. Identiﬁcation and
assessment of Anderson-Fabry disease by cardiovascular magnetic
resonance noncontrast myocardial T1 mapping. Circulation
Cardiovascular imaging. 2013; 6:392–8. [PubMed: 23564562]
169. Jianxiong Zhang, Yunxiao Li, Qiufen Xu, et al. Cardiac
Magnetic Resonance Imaging for Diagnosis of Cardiac Sarcoidosis: A
Meta-Analysis. Canadian Respiratory Journal Volume 2018, 10.

170. Leong DP, Chakrabarty A, Shipp N, et al. Effects of myocardial
ﬁbrosis and ventricular dyssynchrony on response to therapy in new-
presentation idiopathic dilated cardiomyopathy: insights from
cardiovascular magnetic resonance and echocardiography. European
heart journal. 2012; 33:640–8
171. Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization
therapy guided by late gadolinium enhancement cardiovascular
magnetic resonance. Journal of cardiovascular magnetic resonance
ofﬁcial journal of the Society for Cardiovascular Magnetic Resonance.
2011; 13:29
172. Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall
ﬁbrosis as a predictor of mortality and morbidity after cardiac
resynchronization therapy in patients with nonischemic
cardiomyopathy. Journal of the American College of Cardiology. 2012;
60:1659–67
173. Daoulah A, Alsheikh-Ali AA, Al-Faiﬁ SM, Ocheltree SR, Haq E,
Asrar FM, Fathey A, Haneef AA, Al Mousily F, O el-S, Lotﬁ A. Cardiac
resynchronization therapy in patients with postero-lateral scar by
cardiac magnetic resonance: A systematic review and meta-analysis. J
Electrocardiol. 2015 Sep-Oct;48(5):783-90. doi: 10.1016
174. Acosta J, Fernández-Armenta J, Borràs R, Anguera I, Bisbal F,
Martí-Almor J, Tolosana JM, Penela D, Andreu D, Soto-Iglesias D,
Evertz R, Matiello M, Alonso C, Villuendas R, de Caralt TM, Perea RJ,
Ortiz JT, Bosch X, Serra L, Planes X, Greiser A, Ekinci O, Lasalvia L,
Mont L, Berruezo A. Scar Characterization to Predict Life-Threatening
Arrhythmic Events and Sudden Cardiac Death in Patients With
Cardiac Resynchronization Therapy: The GAUDI-CRT Study. JACC
Cardiovasc Imaging. 2018 Apr;11(4):561-572. doi: 10.1016
175. Hoke U, Khidir MJ, van der Geest RJ, Schalij MJ, Bax JJ, Delgado
V, Ajmone Marsan N. Relation of Myocardial Contrast-Enhanced T1
Mapping by Cardiac Magnetic Resonance to Left Ventricular Reverse
Remodeling After Cardiac Resynchronization Therapy in Patients
With Nonischemic Cardiomyopathy.
176. Nguyen UC, Maﬁ-Rad M, Aben JP, Smulders MW, Engels EB,
van Stipdonk AM, Luermans JG, Bekkers SC, Prinzen FW, Vernooy K. A
novel approach for left ventricular lead placement in cardiac
resynchronization therapy: Intraprocedural integration of coronary

venous electroanatomic mapping with delayed enhancement cardiac
magnetic resonance imaging. Heart Rhythm. 2017 Jan;14(1):110-119.
doi: 10.1016.
177. Kockova R, Sedláček K, Wichterle D, Šikula V, Tintěra J, Jansová
H, Pravečková A, Langová R, Krýže L, El-Husseini W, Segeťová M,
Kautzner J. Cardiac resynchronization therapy guided by cardiac
magnetic resonance imaging: A prospective, single-centre
randomized study (CMR-CRT). Int J Cardiol. 2018 Nov 1;270:325-330.
178. Iles L, Pﬂuger H, Lefkovits L, et al. Myocardial ﬁbrosis predicts
appropriate device therapy in patients with implantable cardioverter-
deﬁbrillators for primary prevention of sudden cardiac death. Journal
of the American College of Cardiology. 2011; 57:821–8.
179. Disertori M, Rigoni M, Pace N, Casolo G, Masè M, Gonzini L, et
al. Myocardial ﬁbrosis assessment by LGE is a powerful predictor of
ventricular tachyarrhythmias in ischemic and nonischemic LV
dysfunction. A meta-analysis. J Am Coll Cardiol Img. 2016;9:1046-
1055. Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan
NA, Kaandorp TA, et al.
180. Roes SD, Borleffs CJ, van der Geest RJ, Westenberg JJ, Marsan
NA, Kaandorp TA, et alInfarct tissue heterogeneity assessed with
contrast-enhanced MRI predicts spontaneous ventricular arrhythmias
in patients with ischemic cardiomyopathy and implantable
cardioverter-deﬁbrillator. Circ Cardiovasc Imaging. 2009;2:183-190.
181. Demirel F, Adiyaman A, Timmer JR, Dambrink JH, Kok M,
Boeve WJ, et al. Myocardial scar characteristics based on cardiac
magnetic resonance imaging is associated with ventricular
tachyarrhythmia in patients with ischemic cardiomyopathy. Int J
Cardiol. 2014;177:392-399.
182. Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late
gadolinium enhancement cardiac magnetic resonance imaging for the
prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur
J Heart Fail. 2013;15:1019-1027.
183. Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure. The SOLVD
investigators. N Engl J Med. 1991;325 (5):293–302.

184. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP,
McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators.
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart
Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi:
10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J
Med. 2019 Mar 14;380(11):1090
185. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan,
captopril,or both in myocardial infarction complicated by heart
failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349
(20):1893–1906.
186. Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of Valsartan
on Morbidity and Mortality in Patients With Heart Failure Not
Receiving Angiotensin-Converting Enzyme inhibitors J Am Coll
Cardiol. 2002;40 (8):1414–1421
187. Dimopoulos K, Saukhe TV, Coats A et al. Meta-analyses of
mortality and morbidity effects of an angiotensin receptor blocker in
patients with chronic heart failure already receiving an ACE inhibitor
(alone or with a beta-blocker). Int J Cardiol. 2004; 93 (2–3):105-111
188. Effects of enalapril on mortality in severe congestive heart
failure: results of the Cooperative North Scandinavian Enalapril
Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N
Engl J Med. 1987;316 (23):1429–1435.
189. Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor
Trials. Overview of randomized trials of angiotensin-converting
enzyme inhibitors on mortality and morbidity in patients with heart
failure JAMA. 1995;273 (18):1450–1456.
190. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G.,
Horowitz J.D., Massie B.M., Rydén L., Thygesen K., Uretsky B.F.
Comparative effects of low and high doses of the angiotensin-
converting enzyme inhibitor, lisinopril, on morbidity and mortality in
chronic heart failure. ATLAS Study Group. Circulation 1999 Dec
7;100(23):2312-8.
191. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril
on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction: results of the Survival And
Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med.
1992;327 (10):669–677.

192. Effect of enalapril on mortality and the development of heart
failure in asymptomatic patients with reduced left ventricular ejection
fractions. The SOLVD investigators. N Engl J Med. 1992;327(10):685–
691.
193. Effect of ramipril on mortality and morbidity of survivors of
acute myocardial infarction with clinical evidence of heart failure. The
Acute Infarction Ramipril Efﬁcacy (AIRE) Study Investigators. Lancet.
1993;342 (8875):821–828.
194. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L,
Taylor J. The perindopril in elderly people with chronic heart failure
(PEP-CHF) study. Eur Heart J 2006;27:2338–2345.
195. Pﬂugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt
B.Clinical consequences of angiotensin-converting enzyme inhibitor
withdrawal in chronic heart failure: a double-blind, placebo-
controlled study of quinapril. The Quinapril Heart Failure Trial
Investigators.J Am Coll Cardiol. 1993 Nov 15;22(6):1557-63. doi:
10.1016/0735-1097(93)90578-o.
196. Widimský J, Kremer HJ, Jerie P, Uhlír O. Czech and Slovak
spirapril intervention study (CASSIS). A randomized, placebo and
active-controlled, double-blind multicentre trial in patients with
congestive heart failure. Eur J Clin Pharmacol. 1995; 49(1-2):95-102.
doi: 10.1007/BF00192366.
197. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M.
Fosinopril attenuates clinical deterioration and improves exercise
tolerance in patients with heart failure. Fosinopril Efﬁcacy/Safety
Trial (FEST) Study Group. Eur Heart J. 1995 Dec;16(12):1892-9. doi:
10.1093/oxfordjournals.eurheartj.a060844.
198. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P.,
Rizkala A.R., Rouleau J.L.,Shi V.C., Solomon S.D., Swedberg K., Zile
M.R., PARADIGM-HF Investigators and Committees. Angiotensin-
neprilysin inhibition versus enalapril in heart failure. N Engl J Med
2014;371: 993–1004.
199. Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol
Heart Failure Study Group. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl J Med 1996;
334 (21):1349–1355.

200. Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical
outcomes in patients on beta-blocker therapy admitted with
worsening chronic heart failure. Am J Cardiol. 2003;91 (2):169–174.
201. The Cardiac Insufﬁciency Bisoprolol Study II (CIBIS-II): a
randomized trial. Lancet 1999;353 (9146):9–13.
202. Dargie H.J. Effect of carvedilol on outcome after myocardial
infarction in patients with left ventricular dysfunction: the
CAPRICORN randomized trial. Lancet 2001; 357:1385-1390.
203. Jondeau G., Neuder Y., Eicher J.C. et al. B-CONVINCED:
Betablocker CONtinuation Vs. INterruption in patients with
Congestive heart failure hospitalizED for a decompensation episode.
Eur Heart J. 2009;30 (18):2186–2192
204. Pitt B., Zannad F., Remme W.J. et al. The effect of
spironolactone on morbidity and mortality in patients with severe
heart failure. Randomized Aldactone Evaluation Study Investigators.
N Engl J Med. 1999;341 (10):709–717.
205. Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients
with systolic heart failure and mild symptoms. N Engl J Med. 2011;364
(1):11–21.
206. Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of
hyperkalemia after publication of the Randomized Aldactone
Evaluation Study. N Engl J Med. 2004;351 (6):543–551
207. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L.,
Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S., Anand
I.S., Bělohlávek J., Böhm M., Chiang C.-E., Chopra V.K., de Boer R.A.,
Desai A.S., Diez M., Drozdz J., Dukát A., Ge J., Howlett J.G., Katova T.,
Kitakaze M., Ljungman C.E.A., Merkely B., Nicolau J.C., O’Meara E.,
Petrie M.C., Vinh P.N, Schou M., Tereshchenko S., Verma S., Held C.,
DeMets D.L., Docherty K.F., Jhund P.S., Bengtsson O., Sjöstrand M.,
Langkilde A.-M. Dapagliﬂozin in Patients with Heart Failure and
Reduced
Ejection
Fraction.
September
19,
2019
DOI:
10.1056/NEJMoa1911303
208. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P.,
Coats A.. Current evidence supporting the role of diuretics in heart
failure: a meta analysis of randomized controlled trials. Int J Cardiol
2002;82:149–158.

209. Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J.
Diuretics for heart failure.Cochrane Database Syst Rev
2012;2:CD003838.
210. Dormans T.P., van Meyel J.J., Gerlag P.G. et al. Diuretic efﬁcacy
of high dose furosemide in severe heart failure: bolus injection versus
continuous infusion. J Am Coll Cardiol. 1996;28 (2):376–382
211. Vargo D.L., Kramer W.G., Black P.K. et al. Bioavailability,
pharmacokinetics, and pharmacodynamics of torsemide and
furosemide in patients with congestive heart failure. Clin Pharmacol
Ther.1995;57 (6):601–609.
212. Patterson J.H., Adams K.F. Jr, Applefeld M.M. et al. for the
Torаsemide Investigators Group. Oral torsemide in patients with
chronic congestive heart failure: effects on body weight, edema, and
electrolyte excretion. Pharmacotherapy. 1994;14 (5):514–521
213. Brater D. Torasemid: pharmacokinetic and clinical efﬁcacy. Eur
J Heart Fail. 2001;3 (Suppl G): 19–24.
214. Cosin J., Diez J., Torasemide in chronic heart failure: results of
the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513
215. Fortuno A., Muniz P., Ravassa S. et al. Torasemide inhibits
angiotensin II-induced vasoconstriction and intracellular calcium
increase in the aorta of spontaneously hypertensive rats.
Hypertension.1999;34 (1):138–143.
216. Yamato M., Sasaki T., Honda K. et al. Effects of torasemide on
left ventricular function and neurohumoral factors in patients with
chronic heart failure. Circ J. 2003;67 (5):384–390
217. Granger C.B., McMurray J.J., Yusuf S. et al. Effects of
candesartan in patients with chronic heart failure and reduced left-
ventricular systolic function intolerant to angiotensin-converting-
enzyme inhibitors: the CHARM–Alternative trial. Lancet. 2003;362
(9386):772–776.
218. Cohn J.N., Tognoni G. A randomized trial of the
angiotensinreceptor blocker valsartan in chronic heart failure. N Engl
J Med.2001; 345 (23):1667–1675
219. McMurray J.J., Ostergren J., Swedberg K. et al. Effects of
candesartan in patients with chronic heart failure and reduced
leftventricular systolic function taking angiotensin-convertingenzyme

inhibitors: the CHARM–Added trial. Lancet. 2003; 362 (9386):767–
771.
220. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M,
Lopez-Sendon J, Reil J-C, Swedberg K, Tavazzi L. Heart rate at
baseline inﬂuences the effect of ivabradine on cardiovascular
outcomes in chronic heart failure: analysis from the SHIFT study. Clin
Res Cardiol 2013; 102:11–22
221. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and
outcomes in chronic heart failure (SHIFT): a randomised placebo-
controlled study. Lancet 2010; 376 (9744):875–885
222. Swedberg K, Komajda M, Böhm M, Borer J, Robertson M,
Tavazzi L, Ford I. Effects on outcomes of heart rate reduction by
ivabradine in patients with congestive heart failure: is there an
inﬂuence of beta-blocker dose?: ﬁndings from the SHIFT (Systolic
Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
J Am Coll Cardiol 2012;59:1938–1945
223. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL
Investigators. Ivabradine for patients with stable coronary artery
disease and left-ventricular systolic dysfunction (BEAUTIFUL): a
randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep
6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008
Aug 29
224. Digoxin"s effect on mortality and hospitalization in heart
failure: implications of the DIG study. Digitalis Investigation Group.
Cleve Clin J Med. 1997 May; 64 (5):234-7.
225. Gheorghiade M., Fonarow G.C., van Veldhuisen D.J. et al. Lack
of evidence of increased mortality among patients with atrial
ﬁbrillation taking digoxin: ﬁndings from post hoc propensity-matched
analysis of the AFFIRM trial. Eur Heart J. 2013;34 (20):1489–1497
226. Jorge E., Baptista R., Martins H. et al. Digoxin in advanced
heart failure patients: a question of rhythm. Rev Port Cardiol. 2013;32
(4):303–310
227. Gheorghiade M., Patel K., Filippatos G. et al. Effect of oral
digoxin in high-risk heart failure patients: a pre-speciﬁed subgroup
analysis of the DIG trial. Eur J Heart Fail. 2013;15 (5):551–559

228. Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum
digoxin concentration and outcomes in patients with heart failure.
JAMA. 2003;289 (7):871–878.
229. Adams K.F., Patterson J.H., Gattis W.A. et al. Relationship of
serum digoxin concentration to mortality and morbidity in women in
the digitalis investigation group trial: a retrospective analysis. J Am
Coll Cardiol. 2005;46 (3):497–504.
230. Malik A, Masson R, Singh S, Wu W, Packer M, Pitt B, Waagstein
F, . Morgan C, Allman R, Fonarow G, Ahmed A. Digoxin
Discontinuation and Outcomes in Patients With Heart Failure With
Reduced Ejection Fraction. Journal of the American College of
Cardiology Aug 2019, 74 (5) 617-627; DOI: 10.1016/j.jacc.2019.05.064
231. The GISSI-HF investigators. Effect of n-3 polyunsaturated fatty
acids in patients with chronic heart failure (the GISSI-HF trial): a
randomized, double-blind, placebo-controlled trial. Lancet
2008;372:1223―30.
232. Lucas M, Kimmig M, Karalis G. Do omega-3 polyunsaturated
fatty acids prevent cardiovascular disease? A review of the
randomized clinical trials. Lipid Insights 2013;6:13–20
233. Cohn J.N., Archibald D.G., Ziesche S. et al. Effect of vasodilator
therapy on mortality in chronic congestive heart failure: results of a
Veterans Administration Cooperative Study. N Engl J Med 1986;314
(24):1547–1552.
234. Taylor A.L., Ziesche S., Yancy C. et al. Combination of
isosorbide dinitrate and hydralazine in blacks with heart failure. N
Engl J Med. 2004;351 (20):2049–2057.
235. Carson P., Ziesche S., Johnson G., Cohn J.N., for the Vasodilator
–Heart Failure Trial Study Group. Racial differences in response to
therapy for heart failure: analysis of the vasodilator-heart failure
trials. J Card Fail 1999;5 (3):178–187
236. Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the
treatment of heart failure? Controlled rosuvastatin multinational
study in heart failure (CORONA): Study design and baseline
characteristics. Eur J Heart Fail 2005;7 (6):1059–1069.

237. Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of
rosuvastatin in patients with chronic heart failure (the GISSI–HF
trial): a randomised, double-blind, placebo-controlled trial. Lancet.
2008; 372 (9645):1231–1239.
238. Homma S., Thompson J.L., Pullicino P.M. et al, WARCEF
Investigators.Warfarin and aspirin in patients with heart failure and
sinus rhythm. N Engl J Med 2012;366 (20):1859–1869
239. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade
M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van
Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators.
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and
Coronary Disease. N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi:
10.1056/NEJMoa1808848.
240. Sulaica EM, Macaulay TE, Helbing RR, Abo-Aly M, Abdel-Latif
A45, Wanat MA. A comparison of anticoagulation, antiplatelet, and
placebo treatment for patients with heart failure reduced ejection
fraction in sinus rhythm: a systematic review and meta-analysis.
Heart Fail Rev. 2019 Jun 29. doi: 10.1007/s10741-019-09818-w. [Epub
ahead of print
241. Gheorghiade M., Böhm M., Greene S.J., Fonarow G.C., Lewis
E.F., Zannad F.,Solomon S.D., Baschiera F., Botha J., Hua T.A.,
Gimpelewicz C.R., Jaumont X., Lesogor A., Maggioni A.P.;
ASTRONAUT Investigators and Coordinators. Effect of aliskiren on
postdischarge mortality and heart failure readmissions among
patients hospitalized for heart failure: the ASTRONAUT randomized
trial. JAMA. 2013 Mar 20;309(11):1125-35.
242. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D.,
Haffner S.M., Solomon S.D., Chaturvedi N., Persson F., Desai A.S.,
Nicolaides M., Richard A., Xiang Z., Brunel P., Pfeffer M.A.;
ALTITUDEInvestigators. Cardiorenal end points in a trial of aliskiren
for type 2 diabetes.N Engl J Med. 2012 Dec 6;367(23):2204-13. 131
243. Komajda M., McMurray J.J., Beck-Nielsen H., Gomis R.,
Hanefeld M., Pocock S.J.,Curtis P.S., Jones N.P., Home P.D. Heart
failure events with rosiglitazone in type 2 diabetes: data from the
RECORD clinical trial. Eur Heart J 2010;31:824–831
244. Hernandez A.V., Usmani A., Rajamanickam A., Moheet A.
Thiazolidinediones and risk of heart failure in patients with or at high
risk of type 2 diabetes mellitus: a meta-analysis and meta-regression

analysis of placebo-controlled randomized clinical trials. Am J
Cardiovasc Drugs 2011;11:115–128
245. Erdmann E., Charbonnel B., Wilcox R.G., Skene A.M., Massi-
Benedetti M., Yates J.,Tan M., Spanheimer R., Standl E., Dormandy
J.A. Pioglitazone use and heart failure in patients with type 2 diabetes
and preexisting cardiovascular disease: data from the PROactive study
(PROactive 08). Diabetes Care 2007;30:2773–2778.139-141
246. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem
increases late-onset congestive heart failure in postinfarction patients
with early reduction in ejection fraction. The Adverse Experience
Committee; and the Multicenter Diltiazem Postinfarction Research
Group. Circulation 1991;83:52–60
247. Cohn J.N., Ziesche S., Smith R. et al. Effect of the calcium
antagonist felodipine as supplementary vasodilator therapy in
patients with chronic heart failure treated with enalapril: V-HeFT III.
Vasodilator – Heart Failure Trial (V-HeFT) Study Group. Circulation.
1997;96 (3):856–863
248. Thackray S., Witte K., Clark A.L., Cleland J.G. Clinical trials
update: OPTIME–CHF, PRAISE-2, ALL–HAT. Eur J Heart Fail.
2000;2(2):209–212.
249. Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine
on morbidity and mortality in severe chronic heart failure. Prospective
Randomized Amlodipine Survival Evaluation Study Group. N Engl J
Med. 1996; 335 (15):1107–1114
250. Huerta C., Varas-Lorenzo C., Castellsague J., Garcia Rodriguez
L.A. Non-steroidal anti-inﬂammatory drugs and risk of ﬁrst hospital
admission for heart failure in the general population. Heart
2006;92:1610–1615
251. Preliminary report: effect of encainide and ﬂecainide on
mortality in a randomized trial of arrhythmia suppressionafter
myocardial infarction. The Cardiac Arrhythmia Suppression Trial
(CAST) Investigators. N Engl J Med. 1989;321(6):406-12
252. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-
Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene
H.L., et al. Mortality and morbidity in patients receiving encainide,
ﬂecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N
Engl J Med. 1991 Mar 21;324(12):781-8

253. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure.
European
Heart
Journal
(2016)
37,
2129–2200
doi:10.1093/eurheartj/ehw128
254. Cleland JGF, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser
RS, Chattopadhyay S, Norell MS, Pennell DJ, Senior R. The heart
failure revascularization trial (HEART). Eur J Heart Fail 2011;13:227–
233
255. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A,
Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D,
Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L,
Bonow RO, Rankin GR, Jones RH, Rouleau J-L, STICH Investigators.
Coronary-artery bypass surgery in patients with left ventricular
dysfunction. N Engl J Med 2011;364:1607–1616
256. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ,
Lee KL, Borges-Neto S, Farsky PS, Jones RH, Berman DS, Bonow RO.
Inducible myocardial ischemia and outcomes in patients with
coronary artery disease and left ventricular dysfunction. J Am Coll
Cardiol 2013;61:1860–1870
257. Carson P, Wertheimer J, Miller A, O’Connor CM, Pina IL,
Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ.
The STICH trial (Surgical Treatment for Ischemic Heart Failure):
mode-of-death results. JACC Heart Fail 2013;1: 400–408
258. Packer M. Effect of carvedilol on the morbidity of patients with
severe chronic heart failure: results of the Carvedilol Prospective
Randomized Cumulative Survival (COPERNICUS) Study. Circulation
2002;106:2194–2199
259. Poole – Wilson P.A., Swedberg K., Cleland J.G. et al.
Comparison of carvedilol and metoprolol on clinical outcomes in
patients with chronic heart failure in the Carvedilol Or Metoprolol
European Trial (COMET): randomised controlled trial. Lancet
2003;362(9377):7–13.
260. Desai AS, McMurray JJ, Packer M. et al. Effect of the
angiotensin-receptor-neprilysin inhibitor LCZ696 compared with
enalapril on mode of death in heart failure patients. Eur Heart J. 2015
Aug 7;36(30):1990-7. doi: 10.1093/eurheartj/ehv186.

261. Wyse D., Friedman P.L., Epstein A.E. A comparison of
antiarrhythmic-drug therapy with implantable deﬁbrillators in
patients resuscitated from near-fatal ventricular arrhythmias. The
Antiarrhythmics
versus
Implantable
Deﬁbrillators
(AVID)
Investigators. N Engl J Med 1997;337:1576–1583
262. Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck
K.H., Zipes D.P., Greene H.L., Boczor S., Domanski M., Follmann D.,
Gent M., Roberts R.S. Meta-analysis of the implantable cardioverter
deﬁbrillator secondary prevention trials. AVID, CASH and CIDS
studies. Antiarrhythmics vs Implantable Deﬁbrillator study. Cardiac
Arrest Study Hamburg. Canadian Implantable Deﬁbrillator Study. Eur
Heart J 2000;21:2071–2078
263. Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon
R.S., Mitchell L.B.,Green M.S., Klein G.J., O’Brien B. Canadian
implantable deﬁbrillator study (CIDS): a randomized trial of the
implantable cardioverter deﬁbrillator against amiodarone.Circulation
2000;101:1297–1302
264. Kuck K.H., Cappato R., Siebels J., Ru¨ppel R. Randomized
comparison of antiarrhythmic drug therapy with implantable
deﬁbrillators in patients resuscitated from cardiac arrest: the Cardiac
Arrest Study Hamburg (CASH). Circulation 2000;102: 748–754
265. Oseroff O., Retyk E., Bochoeyer A. Subanalyses of secondary
prevention
implantable
cardioverter-deﬁbrillator
trials:
antiarrhythmics versus implantable deﬁbrillators (AVID), Canadian
Implantable Deﬁbrillator Study (CIDS), and Cardiac Arrest Study
Hamburg (CASH). Curr Opin Cardiol 2004;19:26–30
266. Al-Khatib SM, Sanders GD, Mark DB et al. Implantable
cardioverter deﬁbrillators and cardiac resynchronization therapy in
patients with left ventricular dysfunction: randomized trial evidence
through 2004. Am Heart J. 2005 Jun;149(6):1020-34. DOI:
10.1016/j.ahj.2005.02.005.
267. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland
JGF, Dargie HJ, Granger CB, Kjekshus J, Kober L, Latini R, Maggioni
AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J,
Zannad F, Zile MR, McMurray JJV. Declining risk of sudden death in
heart
failure.
N
Engl
J
Med.
2017;377:41–51.
doi:
10.1056/NEJMoa1609758.

268. Lafuente-Lafuente C, Valembois L, Bergmann J-F, Belmin J.
Antiarrhythmics for maintaining sinus rhythm after cardioversion of
atrial ﬁbrillation. Cochrane Database Syst Rev 2012;5:CD005049
269. Increased mortality after dronedarone therapy for severe heart
failure, ﬂecainide and propafenone in patients with cardiac disease
and complex ventricular arrhythmias. Antiarrhythmic Drug
Evaluation Group (A.D.E.G.). Eur Heart J 1992; 13:1251–1258
270. Kober L, Torp-Pedersen C, McMurray JJV, Gøtzsche O, Le´vy S,
Crijns H, Amlie J,,Carlsen J. Increased mortality after dronedarone
therapy for severe heart failure. N Engl J Med 2008;358:2678–2687
271. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman
SA. Heart failure decompensation and all-cause mortality in relation
to percent biventricular pacing in patients with heart failure: is a goal
of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009 Jan
27;53(4):355-60. doi: 10.1016/j.jacc.2008.09.043
272. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L.,
Boineau R., Domanski M., Troutman C., Anderson J., Johnson G.,
McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S.,
Fishbein D.P., Luceri R.M., Ip JH. Amiodarone or an implantable
cardioverter–deﬁbrillator for congestive heart failure. N Engl J
Med2005;352:225–237
273. Torp-Pedersen C., Metra M., Spark P., Lukas M.A., Moullet C.,
Scherhag A., Komajda M., Cleland JGF, Remme W., Di Lenarda A.,
Swedberg K., Poole-Wilson P.A. The safety of amiodarone in patients
with heart failure. J Card Fail 2007;13:340–345
274. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD,
Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in
patients with congestive heart failure and asymptomatic ventricular
arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive
Heart Failure. N Engl J Med 1995;333:77–82
275. Deyell MW, Park KM, Han Y, Frankel DS, Dixit S, Cooper JM,
Hutchinson MD, Lin D, Garcia F, Bala R, Riley MP, Gerstenfeld E,
Callans DJ, Marchlinski FE. Predictors of recovery of left ventricular
dysfunction after ablation of frequent ventricular premature
depolarizations. Heart Rhythm 2012;9:1465–1472

276. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C,
ArmstrongW, Good E, Chugh A, Jongnarangsin K, Pelosi F Jr.,
Crawford T, Ebinger M, Oral H, Morady F, Bogun F. Relationship
between burden of premature ventricular complexes and left
ventricular function. Heart Rhythm 2010;7:865–869
277. Ban JE, Park HC, Park JS, Nagamoto Y, Choi JI, Lim HE, Park
SW, Kim YH. Electrocardiographic and electrophysiological
characteristics of premature ventricular complexes associated with
left ventricular dysfunction in patients without structural heart
disease. Europace 2013;15:735–741
278. Chatterjee S., Ghosh J., Lichstein E., Aikat S., Mukherjee D.
Meta-analysis of cardiovascular outcomes with dronedarone in
patients with atrial ﬁbrillation or heart failure. Am J Cardiol
2012;110:607–613
279. Atti V, Vuddanda V, Turagam MK, Vemula P, Shah Z, Nagam H,
Yandrapalli S, Jazayeri MA, Koerber S, Gonzalez JV, Natale A, Di Biase
L, Lakkireddy DR. Prophylactic catheter ablation of ventricular
tachycardia in ischemic cardiomyopathy: a systematic review and
meta-analysis of randomized controlled trials. J Interv Card
Electrophysiol. 2018 Nov;53(2):207-215. doi: 10.1007/s10840-018-
0376-5. Epub 2018 Apr 21
280. Santangeli P, Muser D, Maeda S, Filtz A, Zado ES, Frankel DS,
Dixit S, Epstein AE, Callans DJ, Marchlinski FE. Comparative
effectiveness of antiarrhythmic drugs and catheter ablation for the
prevention of recurrent ventricular tachycardia in patients with
implantable cardioverter-deﬁbrillators: A systematic review and
meta-analysis of randomized controlled trials. Heart Rhythm. 2016
Jul;13(7):1552-9. doi: 10.1016/j.hrthm.2016.03.004. Epub 2016 Mar 4.
Review
281. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES,
Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser
SH; Optimal Pharmacological Therapy in Cardioverter Deﬁbrillator
Patients (OPTIC) Investigators. Comparison of beta-blockers,
amiodarone plus beta-blockers, or sotalol for prevention of shocks
from implantable cardioverter deﬁbrillators: the OPTIC Study: a
randomized
trial.JAMA.
2006;
295:165–171.
doi:
10.1001/jama.295.2.165.

282. Dinov B, Fiedler L, Schonbauer R, Bollmann A, Rolf S,
Piorkowski C, Hindricks G, Arya A. Outcomes in catheter ablation of
ventricular tachycardia in dilated nonischemic cardiomyopathy
compared with ischemic cardiomyopathy: results from the Prospective
Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 2014;
129:728–736
283. Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M.
Bundle branch reentrant ventricular tachycardia: cumulative
experience in 48 patients. J Cardiovasc Electrophysiol 1993;4:253–
262.
284. Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P,
Akhtar M. Sustained bundle branch reentry as a mechanism of clinical
tachycardia. Circulation 1989;79:256–270.
285. Proietti R, Essebag V, Beardsall J, Hache P, Pantano A,
Wulffhart Z, Juta R, Tsang B, Joza J, Nascimento T, Pegoraro V,
Khaykin Y, Verma A. Substrate-guided ablation of haemodynamically
tolerated and untolerated ventricular tachycardia in patients with
structural heart disease: effect of cardiomyopathy type and acute
success on long-term outcome. Europace. 2015;17:461–467.
286. Tchou P, Jazayeri M, Denker S, Dongas J, Caceres J, Akhtar M.
Transcatheter electrical ablation of right bundle branch. A method of
treating macroreentrant ventricular tachycardia attributed to bundle
branch reentry. Circulation 1988;78: 246–257.
287. Tzou WS, Tung R, Frankel DS, Vaseghi M, Bunch TJ, Di Biase L,
Tholakanahalli VN, Lakkireddy D, Dickfeld T, Saliaris A, Weiss JP,
Mathuria N, Tedrow U, Afzal MR, Vergara P, Nagashima K, Patel M,
Nakahara S, Vakil K, Burkhardt JD, Tseng CH, Natale A, Shivkumar K,
Callans DJ, Stevenson WG, Della Bella P, Marchlinski FE, Sauer WH
.Ventricular Tachycardia Ablation in Severe Heart Failure: An
International Ventricular TachycardiaAblation Center Collaboration
Analysis Circ Arrhythm Electrophysiol. 2017 Jan;10(1)
288. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Reﬁning
clinical risk stratiﬁcation for predicting stroke and thromboembolism
in atrial ﬁbrillation using a novel risk factor-based approach: the euro
heart survey on atrial ﬁbrillation. Chest 2010; 137:263–272
289. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS,
Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-
Pedersen C. Validation of risk stratiﬁcation schemes for predicting

stroke and thromboembolism in patients with atrial ﬁbrillation:
nationwide cohort study. BMJ 2011;342:d124.
290. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk
stratiﬁcation schemes for ischaemic stroke and bleeding in 182 678
patients with atrial ﬁbrillation: the Swedish Atrial Fibrillation cohort
study. Eur Heart J 2012;33:1500–1510
291. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic
therapy to prevent stroke in patients who have nonvalvular atrial
ﬁbrillation. Ann Intern Med 2007; 146:857–867
292. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J,
Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M,
Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner
CD,Wallentin L, RE-LY Steering Committee and Investigators.
Dabigatran versus warfarin in patients with atrial ﬁbrillation. N Engl J
Med 2009;361:1139–1151
293. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM,
Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz
R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ,
Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan
P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A,
Verheugt FW, Zhu J,Wallentin L, ARISTOTLE Committees and
Investigators. Apixaban versus warfarin in patients with atrial
ﬁbrillation. N Engl J Med 2011;365:981–992
294. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W,
Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC,
Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators.
Rivaroxaban versus warfarin in nonvalvular atrial ﬁbrillation. N Engl J
Med 2011;365:883–891.
295. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD,
Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W,
Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I,
Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban
versus warfarin in patients with atrial ﬁbrillation. N Engl J Med
2013;369:2093–2104
296. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-
vitamin K antagonist oral anticoagulants (NOACs) in patients with
concomitant atrial ﬁbrillation and heart failure: a systemic review and

meta-analysis of randomized trials. Eur J Heart Fail 2015;17:1192–
1200
297. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu
N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A,
Yamashita T, Antman EM. Comparison of the efﬁcacy and safety of
new oral anticoagulants with warfarin in patients with atrial
ﬁbrillation: a meta-analysis of randomised trials. Lancet 2014;383:
955–962
298. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M,
Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly
PA, Yang S, Connolly SJ, RE-LY investigators. Efﬁcacy and safety of
dabigatran compared with warfarin at different levels of international
normalised ratio control for stroke prevention in atrial ﬁbrillation: an
analysis of the RE-LY trial. Lancet 2010;376:975–983
299. Pedersen O.D., Bagger H., Køber L., Torp-Pedersen C.
Trandolapril reduces the incidence of atrial ﬁbrillation after acute
myocardial infarction in patients with left ventricular dysfunction.
Circulation 1999; 100:376–380
300. Ducharme A., Swedberg K., Pfeffer M.A., CohenSolal A.,
Granger C.B., Maggioni A.P., Michelson E.L., McMurrayJJ V., Olsson
L., Rouleau J.L., Young J.B., Olofsson B., Puu M., Yusuf S.. Prevention
of atrial ﬁbrillation in patients with symptomatic chronic heart failure
by candesartan in the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) program. Am Heart J
2006;152:86–92.
301. McMurray J., Køber L., Robertson M., Dargie H., Colucci W.,
Lopez-Sendon J., Remme W., Sharpe D.N., Ford I.Antiarrhythmic
effect of carvedilol after acute myocardial infarction. J Am Coll Cardiol
2005;45:525–530.
302. Swedberg K., Zannad F., McMurray J.J.V., Krum H., van
Veldhuisen D.J., Shi H., Vincent J., Pitt B. Eplerenone and atrial
ﬁbrillation in mild systolic heart failure. J Am Coll Cardiol
2012;59:1598–1603.
303. Han M., Zhang Y., Sun S., Wang Z., Wang J., Xie X., Gao M.,
Yin X., Hou Y. Renin–angiotensin system inhibitors prevent the
recurrence of atrial ﬁbrillation. J Cardiovasc Pharmacol 2013;62:405–
415.

304. Brodsky M.A., Allen B.J., Walker C.J., Casey T.P., Luckett C.R.,
Henry W.L. Amiodarone for maintenance of sinus rhythm after
conversion of atrial ﬁbrillation in the setting of a dilated left atrium.
Am J Cardiol 1987;60:572–575
305. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher
R., Singh S.N. Spontaneous conversion and maintenance of sinus
rhythm by amiodarone in patients with heart failure and atrial
ﬁbrillation: observations from the veterans affairs congestive heart
failure survival trial of antiarrhythmic therapy (CHF-STAT). The
Department of Veterans Affairs CHF-STAT Investigators. Circulation
1998;98:2574–2579
306. Shelton R.J., Clark A.L., Goode K., Rigby A.S., Houghton T.,
Kaye G.C., Cleland JGF. A randomised, controlled study of rate versus
rhythm control in patients with chronic atrial ﬁbrillation and heart
failure: (CAFE-II Study).Heart 2009;95:924–930.
307. Capucci A., Villani G.Q., Aschieri D., Rosi A., Piepoli M.F. Oral
amiodarone increases the efﬁcacy of direct-current cardioversion in
restoration of sinus rhythm in patients with chronic atrial ﬁbrillation.
Eur Heart J 2000;21:66–73
308. Hofmann R., Steinwender C., Kammler J., Kypta A., Leisch F.
Effects of a high dose intravenous bolus amiodarone in patients with
atrial ﬁbrillation and a rapid ventricular rate. Int J Cardiol
2006;110:27–32
309. Hofmann R., Wimmer G., Leisch F. Intravenous amiodarone
bolus immediately controls heart rate in patients with atrial
ﬁbrillation accompanied by severe congestive heart failure. Heart
2000;84:635
310. Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP,
Rienstra M, Ranchor AV, Bosker HA, Kamp O, Tijssen JGP, Veeger
NJGM, Van Gelder IC. Rate control versus rhythm control for patients
with persistent atrial ﬁbrillation with mild to moderate heart failure:
results from the RAte Control versus Electrical cardioversion (RACE)
study. Am Heart J 2005;149:1106–1111.
311. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O,
Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP,
Crijns HJGM. A comparison of rate control and rhythm control in
patients with recurrent persistent atrial ﬁbrillation. N Engl J Med
2002;347:1834–1840.

312. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky
B, Hagens VE, Crijns HJGM, RACE and AFFIRM Investigators. Does
intensity of rate-control inﬂuence outcome in atrial ﬁbrillation? An
analysis of pooled data from the RACE and AFFIRM studies. Europace
2006;8:935–942
313. Li S-J, Sartipy U, Lund LH, Dahlstro¨m U, Adiels M, Petzold M,
Fu M. Prognostic signiﬁcance of resting heart rate and use of b-
blockers in atrial ﬁbrillation and sinus rhythm in patients with heart
failure and reduced ejection fraction: ﬁndings from the Swedish Heart
Failure Registry. Circ Heart Fail 2015;8:871–879
314. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe
NR, Robinson K, Yu D, Bass EB. The evidence regarding the drugs used
for ventricular rate control In. J Fam Practice 2000; 49:47–59.
315. Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L.,
Cleland J.G.F., Lip G.Y.H., Coats A.J.S., Andersson B., Kirchhof P.,
vonLueder T.G., Wedel H., Rosano G., Shibata M.C., Rigby A., Flather
M.D. Efﬁcacy of β blockers in patients with heart failure plus atrial
ﬁbrillation:
an
individual-patient
data
meta-analysis.
Lancet2014;384:2235–2243
316. Ziff OJ, Lane DA, Samra M, Grifﬁth M, Kirchhof P, Lip GYH,
Steeds RP, Townend J, Kotecha D. Safety and efﬁcacy of digoxin:
systematic review and meta-analysis of observational and controlled
trial data. BMJ 2015;351:h4451.
317. Sethi NJ, Nielsen EE, Saﬁ S, Feinberg J, Gluud C, Jakobsen JC.
Digoxin for atrial ﬁbrillation and atrial ﬂutter: A systematic review
with meta-analysis and trial sequential analysis of randomised clinical
trials.
PLoS
One.
2018
Mar
8;13(3):e0193924.
doi:
10.1371/journal.pone.0193924. eCollection 2018
318. Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan
M.H., Pires L.A. PAVE Study Group. Left ventricular-based cardiac
stimulation post AV nodal ablation evaluation (the PAVE study). J
Cardiovasc Electrophysiol 2005;16:1160–1165
319. Rationale and design of a study assessing treatment strategies
of atrial ﬁbrillation in patients with heart failure: the Atrial
Fibrillation and Congestive Heart Failure (AF-CHF) trial.Am Heart J.
2002 Oct;144 (4):597-607

320. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L,
Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H,
Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter
Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med.
2018;378:417-427
321. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD,
Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker
GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A,
Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW,
Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-
Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter
Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke,
Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation:
The CABANA Randomized Clinical Trial. JAMA. 2019 Apr
2;321(13):1261-1274. doi: 10.1001/jama.2019.0693
322. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan
KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer
DL; CABANA Investigators. Effect of Catheter Ablation vs Medical
Therapy on Quality of Life Among Patients With Atrial Fibrillation:
The CABANA Randomized Clinical Trial. JAMA. 2019.
323. Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, Dai J, Xu X, Mao
W. Catheter ablation versus medical therapy for patients with
persistent atrial ﬁbrillation: a systematic review and meta-analysis of
evidence from randomized controlled trials. J Interv Card
Electrophysiol. 2018;52:9-18.
324. Cleland JG, Keshavarzi F, Pellicori P, Dicken B. Case selection
for cardiac resynchronization in atrial ﬁbrillation. Heart Fail Clin.
2013;9:461-74.
325. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E,
Occhetta E, Quartieri F, Calò L, Ungar A, Mont L; APAF-CRT
Investigators. A randomized controlled trial of atrioventricular
junction ablation and cardiac resynchronization therapy in patients
with permanent atrial ﬁbrillation and narrow QRS. Eur Heart J.
2018;39:3999-4008
326. Bohm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz
MP et al. Systolic blood pressure, cardiovascular outcomes and
efﬁcacy and safety of sacubitril/valsartan (LCZ696) in patients with

chronic heart failure and reduced ejection fraction: results from
PARADIGM-HF.
Eur
Heart
J.
2017,38
(15):1132-43.
https://doi.org/10.1093/eur-heartj/ehw570.
327. Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on
survival in severe chronic heart failure. N Engl J Med.
2001;344(22):1651–1658.
328. MERIT-HF Study Group. Effects of metoprolol CR / XL in
chronic heart failure: Metoprolol CR / XL Randomized International
Trial in Congestive Heart Failure (MERIT-HF). Lancet
1999;353(9169):2001–2007.
329. Schmieder RE, Rockstroh JK. Efﬁcacy and tolerance of low-dose
loop diuretics in hypertension. Cardiology. 1994;84 Suppl 2:36-42.
330. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative
study on the antihypertensive efﬁcacy of torasemide and indapamide
in patients with essential hypertension. Arzneimittelforschung. 1988
Jan;38(1A):190-3.
331. Thomopoulos C, Parati G, Zanchetti A. Effects of blood
pressure-lowering treatment on cardiovascular outcomes and
mortality: 14 - effects of different classes of antihypertensive drugs in
older and younger patients: overview and meta-analysis. J Hypertens.
2018 Aug;36(8):1637-1647. doi: 10.1097/HJH.0000000000001777
332. Packer, M., Carson, P., Elkayam, U., Konstam, M. A., Moe, G.,
O’Connor, C., DeMets, D. L. (2013). Effect of Amlodipine on the
Survival of Patients With Severe Chronic Heart Failure Due to a
Nonischemic Cardiomyopathy. JACC: Heart Failure, 1(4), 308–314.
doi:10.1016/j.jchf.2013.04.004
333. Physicians Desk Reference. 47th ed. Montvale. NJ: Medical
Economics Company, 1993: 2250.
334. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub
M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality
effect of central sympathetic inhibition with sustained-release
moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail
2003;5:659–667
335. Major cardiovascular events in hypertensive patients
randomized to doxazosin vs chlorthalidone. ALLHAT Collaborative
Research Group. JAMA 2000;283: 1967–1975.

336. Dorszewski A, Go¨hmann E, Dorsz´ewski B, Werner GS, Kreuzer
H, Figulla HR. Vasodilation by urapidil in the treatment of chronic
congestive heart failure in addition to angiotensin-converting enzyme
inhibitors is not beneﬁcial: results of a placebo-controlled, double-
blind study. J Card Fail 1997;3:91–96.
337. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P,
Sutton G. Clinical importance of the renin-angiotensin system in
chronic heart failure: double blind comparison of captopril and
prazosin. Br Med J (Clin Res Ed) 1985;290:1861–1865
338. Kjekshus J, Apetrei E, Barrios V, Bo¨hm M, Cleland JGF, Cornel
JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L,
Hjalmarson A, Hradec J, Ja´nosi A, Kamensky´ G, Komajda M,
Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N,
Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F,
Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic
heart failure. N Engl J Med 2007;357:2248–2261.
339. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for
patients with stable coronary artery disease and left-ventricular
systolic dysfunction (BEAUTIFUL): a randomised, double-blind,
placebo-controlled trial. Lancet 2008;372:807–816.
340. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R.
Relationship between ivabradine treatment and cardiovascular
outcomes in patients with stable coronary artery disease and left
ventricular systolic dysfunction with limiting angina: a subgroup
analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J
2009;30:2337–2345
341. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F,
Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher
RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R,
Haakenson C. A comparison of enalapril with hydralazine-isosorbide
dinitrate in the treatment of chronic congestive heart failure. N Engl J
Med 1991;325:303–310.
342. Vitale C, Spoletini I, MalorniW, Perrone-Filardi P, Volterrani M,
Rosano GMC. Efﬁcacy of trimetazidine on functional capacity in
symptomatic patients with stable exertional angina—the VASCO-
angina study. Int J Cardiol 2013;168:1078–1081.

343. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M,
Volterrani M, Rosano GMC. Trimetazidine improves left ventricular
function and quality of life in elderly patients with coronary artery
disease. Eur Heart J 2004;25: 1814–1821.
344. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-
analysis of randomized controlled trials in heart failure. Heart
2011;97:278–286
345. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE,
Bangalore S. Percutaneous coronary intervention versus optimal
medical therapy in stable coronary artery disease: a systematic review
and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv
2012;5:476–490.
346. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ,
Lee KL, Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK,
Kent DM. Percutaneous coronary interventions for non-acute
coronary artery disease: a quantitative 20-year synopsis and a
network meta-analysis. Lancet 2009;373:911–918
347. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel
et al. Empagliﬂozin, Cardiovascular Outcomes, and Mortality in Type
2 Diabetes. New England Journal of Medicine. 2015;373 (22):2117– 28.
DOI:10.1056 / NEJMoa1504720.
348. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I.
Cardiovascular effects of dapagliﬂozin in patients with type 2 diabetes
and different risk categories: a meta-analysis. Cardiovascular
Diabetology. 2016;15 (1). DOI:10.1186 / s12933‑016‑0356‑y.
349. Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW,
de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR,
Neal B. Canagliﬂozin and Heart Failure in Type 2 Diabetes Mellitus.
Circulation. 2018;138:458-468
350. Masoudi FA. Thiazolidinediones, Metformin, and Outcomes in
Older Patients With Diabetes and Heart Failure: An Observational
Study. Circulation. 2005;111 (5):583–90. DOI:10.1161 / 01. CIR.
0000154542.13412. B1.
351. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson
JA. Improved clinical outcomes associated with metformin in patients
with diabetes and heart failure. Diabetes Care 2005;28:2345_2351.

352. MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S,
Jhund PS, Petrie MC, McMurray JJ V, Petrie JR, McAlister FA.
Treatment of type 2 diabetes and outcomes in patients with heart
failure: a nested case-control study from the U.K. General Practice
Research Database. Diabetes Care 2010;33:1213–1218.
353. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N,
Cucherat M, Boissel J-P, Kassai B, Moreau A, Gueyfﬁer F, Cornu C.
Reappraisal of metformin efﬁcacy in the treatment of type 2 diabetes:
a meta- analysis of randomised controlled trials. PLoS Med
2012;9:e1001204
354. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J,
Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB,
Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK,
Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and
Investigators. Saxagliptin and cardiovascular outcomes in patients
with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
355. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J,
Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK,
Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F,
Peterson ED, Holman RR; TECOS Study Group. Effect of sitagliptin on
cardiovascular outcomes in type 2 diabetes. N Engl J Med
2015;373:232-42
356. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE,
Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B,
Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von
Eynatten M, McGuire DK; CARMELINA Investigators. Effect of
linagliptin vs placebo on major cardiovascular events in adults with
type 2 diabetes and high cardiovascular and renal risk: the
CARMELINA randomized clinical trial. JAMA 2019;321:69-79
357. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina
Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP,
Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A,
Zinman B, Hernandez AF; EXSCEL Study Group. Effects of once-
weekly exenatide on cardiovascular outcomes in type 2 diabetes. N
Engl J Med 2017;377:1228-1239.
358. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann
JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg
WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER

Steering Committee; LEADER Trial Investigators. Liraglutide and
cardiovascular outcomes in type 2 diabetes. N Engl J Med
2016;375:311-322.
359. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober
LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ,
Probstﬁeld JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.
Lixisenatide in patients with type 2 diabetes and acute coronary
syndrome. N Engl J Med 2015;373: 2247-2257.
360. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter
LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O,
Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators.
Semaglutide and cardiovascular outcomes in patients with type 2
diabetes. N Engl J Med 2016;375:1834-1844.
361. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz
FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD,
Tack CJ, Thomsen M, Vilsboll T, Warren ML, Bain SC; PIONEER 6
Investigators. Oral semaglutide and cardiovascular outcomes in
patients
with
type
2
diabetes.
N
Engl
J
Med;doi:10.1056/NEJMoa1901118. Published online ahead of print 11
June 2019.
362. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan
M, Pais P, Probstﬁeld J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D,
Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J,
Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M,
Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P,
Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE,
Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.
Dulaglutide and cardiovascular outcomes in type 2 diabetes
(REWIND): a double-blind, randomised placebo-controlled trial.
Lancet 2019;394:121-130.
363. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R,
Hanselmann A, Nilsson B, Moller JE, Hjort J, Rasmussen J, Boesgaard
TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H,
Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on
left ventricular function in stable chronic heart failure patients with
and without diabetes (LIVE)-a multicentre, doubleblind, randomised,
placebo-controlled trial. Eur J Heart Fail 2017;19:69-77.

364. Margulies KB, Hernandez AF, Redﬁeld MM, Givertz MM,
Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM,
McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI
Heart Failure Clinical Research Network. Effects of liraglutide on
clinical stability among patients with advanced heart failure and
reduced ejection fraction: a randomized clinical trial. JAMA
2016;316:500-508
365. Hawkins NM, Macdonald MR, Petrie MC, Chalmers GW,
Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart
failure and moderate to severe chronic obstructive pulmonary disease:
a randomized controlled trial, Eur J Heart Fail , 2009, vol. 11 (pg. 684-
690)
366. Lainscak M, Podbregar M, Kovacic D, Rozman J, von HS.
Differences between bisoprolol and carvedilol in patients with chronic
heart failure and chronic obstructive pulmonary disease: a
randomized trial, Respir Med , 2011, vol. 105 Suppl. 1(pg. S44-S49)
367. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer
S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between
beta-blockers in patients with chronic heart failure and chronic
obstructive pulmonary disease: a randomized crossover trial, J Am
Coll Cardiol , 2010, vol. 55 (pg. 1780-1787)
368. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-
blockers for chronic obstructive pulmonary disease, Cochrane
Database Syst Rev , 2005pg. CD003566
369. Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Topper A,
Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac
D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T,
Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich
G, Dietz R. , investigators C-E, Project Multicentre Trials in the
Competence Network Heart F. Titration to target dose of bisoprolol vs.
Carvedilol in elderly patients with heart failure: The CIBIS-ELD trial,
Eur J Heart Fail , 2011, vol. 13 (pg. 670-680)].
370. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak
M et al. Clinical proﬁles and outcomes in patients with chronic heart
failure and chronic obstructive pulmonary disease: An efﬁcacy and
safety analysis of SHIFT study. International Journal of Cardiology.
2013;170 (2):182–8. DOI:10.1016 / j. ijcard. 2013.10.068

371. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R,
Maggioni AP, McMurray JJV, O’Connor C, Pfeffer MA, Solomon SD,
Sun Y, Tendera M, van Veldhuisen DJ. Treatment of anemia with
darbepoetin alfa in systolic heart failure. N Engl J Med
2013;368:1210–1219
372. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G,
Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L,
Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD.
Beneﬁcial effects of long-term intravenous iron therapy with ferric
carboxymaltose in patients with symptomatic heart failure and iron
deﬁciency. Eur Heart J 2015;36:657–668.
373. Anker SD, Comin Colet J, Filippatos G, Willenheimer R,
Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J,
Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson
PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure
and iron deﬁciency. N Engl J Med 2009;361:2436–2448
374. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and
bleeding complications in patients with mechanical heart valve
prostheses. Circulation 1994;89:635–641.
375. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB,
Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver
K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML,
Van de Werf F. Dabigatran versus warfarin in patients with mechanical
heart valves. N Engl J Med 2013; 369:1206–14
376. Glassman AH. Cardiovascular Effects of Tricyclic
Antidepressants. Annual Review of Medicine. 1984;35 (1):503–11.
DOI:10.1146 / annurev.me. 35.020184.002443.
377. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V.
Speculations on difference between tricyclic and selective serotonin
reuptake inhibitor antidepressants on their cardiac effects. Is there
any? Curr Med Chem. 1999;6 (6):469–80. PMID:10213794.
378. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA.
The antipsychotic aripiprazole is a potent, partial agonist at the
human 5‑HT1A receptor. Eur J Pharmacol. 2002;441 (3):137–40.
PMID:12063084

379. Gelbrich G, Störk S, Kreißl-Kemmer S, Faller H, Prettin C,
Heuschmann PU, и др. Effects of structured heart failure disease
management on mortality and morbidity depend on patients’ mood:
results from the Interdisciplinary Network for Heart Failure Study:
Effects of structured HF management depend on patients’ mood.. Eur
J Heart Fail. 2014;16(10):1133–41. DOI:10.1002/ejhf.150
380. Savard LA, Thompson DR, Clark AM. A meta-review of
evidence on heart failure disease management programs: the
challenges of describing and synthesizing evidence on complex
interventions. Trials [Интернет]. 2011 [цитируется по 1 февраль
2018 г.];12(1). DOI:10.1186/1745-6215-12-194
381. de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, van
Wijngaarden J, Cornel JH, Zuithoff NPA, и др. Added value of a
physician-and-nurse-directed heart failure clinic: results from the
Deventer–Alkmaar heart failure study. Heart. 2007;93(7):819–25.
DOI:10.1136/hrt.2006.095810
382. Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D, и др.
Effects of exercise training on depression in patients with heart
failure: a systematic review and meta-analysis of randomized
controlled trials: Effects of exercise training on depression in HF: a
systematic review.. Eur J Heart Fail. 2014;16(7):749–57.
DOI:10.1002/ejhf.101
383. Беграмбекова Ю. Л., Мареев В. Ю., Дробижев М. Ю. Школы
для пациентов с сердечной недостаточностью. Есть ли ШАНС
повлиять на депрессию и тревогу? Вторичный (Post-hoc) анализ
исследования ШАНС (Школа и Амбулаторное Наблюдение
больных Сердечной недостаточностью). Журнал Сердечная
Недостаточность. 2016;17(6):433–42. DOI:10.18087/rhfj.2016.6.2281
384. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS,
Callwood DD et al. Safety and Efﬁcacy of Sertraline for Depression in
Patients With Heart Failure. Journal of the American College of
Cardiology. 2010;56 (9):692–9. DOI:10.1016 / j. jacc. 2010.03.068
385. Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F,
Wachter R et al. Effect of Escitalopram on All-Cause Mortality and
Hospitalization in Patients With Heart Failure and Depression: The
MOOD-HF Randomized Clinical Trial. JAMA. 2016;315 (24):2683.
DOI:10.1001 / jama. 2016.7635

386. Heiat A., Gross C.P., Krumholz H.M. Representation of the
elderly, women, and minorities in heart failure clinical trials. Arch.
Intern. Med. 2002, (162):1682-1688
387. Seo WW, Park JJ, Park HA, et al. Guideline-directed medical
therapy in elderly patients with heart failure with reduced ejection
fraction: a cohort study. BMJ Open. 2020; 10(2):e030514. Published
2020 Feb 6. doi:10.1136/bmjopen-2019-030514.
388. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J,
Coats AJS, et al. Beta-blockers in Heart Failure Collaborative Group.
Beta-blockers for heart failure with reduced, mid-range, and
preserved ejection fraction: an individual patient-level analysis of
double-blind randomized trials. Eur Heart J 2018;39:26-35
389. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM,
Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon
SD. Heart failure with mid-range ejection fraction in CHARM:
characteristics, outcomes and effect of candesartan across the entire
ejection fraction spectrum. Eur J Heart Fail. 2018 Aug; 20:1230-1239.
390. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer
NK, O"Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer
MA; TOPCAT Investigators. Inﬂuence of ejection fraction on
outcomes and efﬁcacy of spironolactone in patients with heart failure
with preserved ejection fraction. Eur Heart J. 2016; 37: 455-62.
391. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni
AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redﬁeld MM, Rouleau
JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund
PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova
E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ,
Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF
Investigators and Committees. N Engl J Med. 2019 Oct
24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep
1.PMID: 31475794
392. Ahmed A1, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW,
Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin
on morbidity and mortality in diastolic heart failure: the ancillary
digitalis investigation group trial. Circulation. 2006 Aug 1;
114(5):397-403. DOI: 10.1161/CIRCULATIONAHA.106.628347

393. Azizova A.G., Ovchinnikov A.G., Blankova Z.N., Ageev F.T. In
patients with elevated LV ﬁlling pressure loop diuretics improve
severity of heart failure and diastolic dysfunction, but torasemide
does it somewhat better than furosemide. Eur J Heart Fail 2011;10
(Suppl 2):S186.
394. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A,
Yadav C, et al. Wireless pulmonary artery pressure monitoring guides
management to reduce decompensation in heart failure with
preserved ejection fraction. Circ Heart Fail. 2014 Nov;7(6):935-44.
doi: 10.1161/CIRCHEARTFAILURE.113.001229.
395. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ,
Parkhomenko A, Borbola J, et al, SENIORS Investigators. Randomized
trial to determine the effect of nebivolol on mortality and
cardiovascular hospital admission in elderly patients with heart
failure (SENIORS). Eur Heart J 2005;26:215–225.
396. Mulder BA, van Veldhuisen DJ, Crijns HJGM, Bo¨hm M, Cohen-
Solal A, Babalis D, Roughton M, Flather MD, Coats AJS, Van Gelder IC.
Effect of nebivolol on outcome in elderly patients with heart failure
and atrial ﬁbrillation: insights from SENIORS. Eur J Heart Fail
2012;14:1171–1178.
397. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis
D, Roughton M, Coats AJS, Poole-Wilson PA, Flather MD. Beta-
blockade with nebivolol in elderly heart failure patients with impaired
and preserved left ventricular ejection fraction. J Am Coll Cardiol
2009;53:2150–2158.
398. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett
B, et al. Spironolactone for heart failure with preserved ejection
fraction. N Engl J Med 2014;370:1383–1392.
399. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P,
McMurray JJ V, Michelson EL, Olofsson B, Ostergren J. Effects of
candesartan in patients with chronic heart failure and preserved left-
ventricular ejection fraction: the CHARM-Preserved Trial. Lancet
2003;362:777–781
400. Hernandez AF, Hammill BG, O"Connor CM, Schulman KA,
Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart
failure: ﬁndings from the OPTIMIZE-HF (Organized Program to
Initiate Lifesaving Treatment in Hospitalized Patients with Heart
Failure) Registry. J Am Coll Cardiol. 2009 Jan 13;53(2):184-92

401. Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT.
Beta-blockers and inhibitors of the renin-angiotensin aldosterone
system for chronic heart failure with preserved ejection fraction.
Cochrane Database Syst Rev 2018 Jun 28;6:CD012721
402 Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni
AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-
Neprilysin Inhibition in Heart Failure with Preserved Ejection
Fraction.
N
Engl
J
Med
2019;381:1609-1620.
doi:
10.1056/NEJMoa1908655.
403. Fadi Hage , Ali Hage , Haissam Haddad , Bob Kiaii. Update on
revascularization in patients with heart failure and coronary artery
disease. Curr Opin Cardiol. 2018 Mar;33(2):232-236. doi:
10.1097/HCO.0000000000000483
404. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza
JA, Michler RE, . Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore
VL, Desvigne-Nickens P, . Sopko G, Rouleau JL; STICHES
Investigators. Coronary-artery bypass surgery in patients with
ischemic cardiomyopathy. N Engl J Med 2016;374:1511–1520.
405. Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, Beaver
TM, Djokovic LT, Wang N, Velazquez EJ, Sopko G, Kron IL, DiMaio JM,
Michler RE, Lee KL, Yii M, Leng CY, Zembala M, Rouleau JL, Daly RC,
Al-Khalidi HR. Inﬂuence of baseline characteristics, operative
conduct, and postoperative course on 30-day outcomes of coronary
artery bypass grafting among patients with left ventricu- lar
dysfunction: Results from the Surgical Treatment for Ischemic Heart
Failure (STICH) Trial. Circulation 2015;132:720–730.
406. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW,
Davis K, Killip T, Passamani E, Norris R, et al. Effect of coronary artery
bypass graft surgery on survival: Overview of 10-year results from
randomised trials by the Coronary Artery Bypass Graft Surgery
Trialists Collaboration. Lancet 1994;344: 563–570
407. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL.
Revascularization in patients with multivessel coronary artery disease
and severe left ventricular sys- tolic dysfunction: Everolimus-eluting
stents versus coronary artery bypass graft surgery. Circulation
2016;133:2132–2140

408. Wolff G, Dimitroulis D, Andreotti F, Kolodziejczak M, Jung C,
Scicchitano P, Devito F, Zito A, Occhipinti M, Castiglioni B, Calveri G,
Maisano F, Ciccone MM, De Servi S, Navarese EP. Survival beneﬁts of
invasive versus conservative strategies in heart failure in patients with
reduced ejection fraction and coronary artery disease: A meta-
analysis. Circ Heart Fail 2017;10:e003255
409. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial
viability testing andimpact of revascularization on prognosis in
patients with coronary artery diseaseand left ventricular dysfunction:
a meta-analysis. J Am Coll Cardiol 2002;39(7):1151–1158
410. Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA,
Pohost GM, . Holly TA, Oh JK, Dagenais F, Milano C, Wrobel K, Pirk J,
Ali IS, Jones RH, . Velazquez EJ, Lee KL, Di Donato M, STICH Trial
Investigators. Insights from the . STICH trial: Change in left
ventricular size after coronary artery bypass grafting . with and
without surgical ventricular reconstruction. J Thorac Cardiovasc Surg .
2013;146:1139–1145.e6
411. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor
CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL,
Lee KL, STICH Hypothesis 2 Investigators. Coronary bypass surgery
with or without surgical ventricular reconstruction. N Engl J Med
2009;360:1705–1717
412. Dor V, Civaia F, Alexandrescu C, Sabatier M, Montiglio F.
Favorable effects of . left ventricular reconstruction in patients
excluded from the Surgical . Treatments for Ischemic Heart Failure
(STICH) trial. J Thorac Cardiovasc Surg . 2011;141:905–916, 916 e1–e4
413. Oh JK, Velazquez EJ, Menicanti L, Pohost GM, Bonow RO, Lin
G, Hellkamp AS, . Ferrazzi P, Wos S, Rao V, Berman D, Bochenek A,
Cherniavsky A, Rogowski J, . Rouleau JL, Lee KL, STICH Investigators.
Inﬂuence of baseline left ventricular . function on the clinical
outcome of surgical ventricular reconstruction in . patients with
ischaemic cardiomyopathy. Eur Heart J 2013;34:39–47.]
414. Cazeau S.,Leclercq C.,Lavergne T.,Walker S.,Varma C.,Linde
C.,Garrigue S .,Kappenberger L.,Haywood G.A.,Santini M.,Bailleul
C.,Mabo P.,Lazarus A.,Ritter P.,Levy T.,McKenna W.,Daubert J-C.
Effects of multisite biventricular pacing in patients with heart failure
and intraventricular conduction delay. N Engl J Med2001;344:873–
880.

415. Сleland J.,Daubert J.,Erdmann E.,Freemantle N.,Gras
D.,Kappenberger L.,Tavazzi L. The effect of cardiac resynchronization
on morbidity and mortality in heart failure. N Engl J Med
2005;352:1539–1549.
416. Cleland JGF, Daubert J-C., Erdmann E., Freemantle N., Gras D.,
Kappenberger L., Tavazzi L. Longer-term effects of cardiac
resynchronization therapy on mortality in heart failure [the CArdiac
REsynchronization-Heart Failure (CARE-HF) trial extension phase].
Eur Heart J 2006;27:1928–1932.
417. Cleland JGF, Freemantle N, Erdmann E, Gras D, Kappenberger
L, Tavazzi L, Daubert J-CC. Long-term mortality with cardiac
resynchronization therapy in the Cardiac Resynchronization–Heart
Failure (CARE-HF) trial. Eur J Heart Fail 2012;14:628–634.
418. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De
Marco T., Carson P., DiCarlo L., DeMets D., White B.G., DeVries D.W.,
Feldman A.M. Cardiac-resynchronization therapy with or without an
implantable deﬁbrillator in advanced chronic heart failure. N Engl J
Med 2004;350:2140–2150.
419. Cleland J.G., Abraham W.T., Linde C., Gold M.R., Young J.B.,
Claude Daubert J., Sherfesee L.,Wells G.A., Tang ASL. An individual
patient meta-analysis of ﬁve randomized trials assessing the effects
of cardiac resynchronization therapy on morbidity and mortality in
patients with symptomatic heart failure. Eur Heart J 2013; 34:3547–
3556.
420. Tang ASL, Wells G.A., Talajic M., Arnold M.O., Sheldon R.,
Connolly S., Hohnloser S.H., Nichol G., Birnie D.H., Sapp J.L., Yee R.,
Healey J.S., Rouleau J.L.Cardiac-resynchronization therapy for mild-
to-moderate heart failure. N Engl J Med 2010;363:2385–2395.
421. Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W.,
Daubert J.P., Estes NAM, Foster E., Greenberg H., Higgins S.L., Pfeffer
M.A., Solomon S.D., Wilber D., ZarebaW. Cardiac-resynchronization
therapy for the prevention of heart-failure events. N Engl J Med
2009;361:1329–1338.
422. Goldenberg I., Kutyifa V., Klein H.U., Cannom D.S., Brown
M.W., Dan A., Daubert J.P., Estes NAM., Foster E., Greenberg H.,
Kautzner J., Klempfner R., Kuniss M., Merkely B., Pfeffer M.A.,
Quesada A., Viskin S., McNitt S., Polonsky B., Ghanem A., Solomon

S.D., Wilber D., ZarebaW., Moss A.J. Survival with cardiac-
resynchronization therapy in mild heart failure. N Engl J Med
2014;370:1694–1701.
423. Linde C., Abraham W.T., Gold M.R, St John Sutton M., Ghio S.,
Daubert C. Randomized trial of cardiac resynchronization in mildly
symptomatic heart failure patients and in asymptomatic patients with
left ventricular dysfunction and previous heart failure symptoms. J
Am Coll Cardiol 2008;52:1834–1843.
424. Daubert C., Gold MR., Abraham W.T., Ghio S., Hassager C.,
Goode G., Szili-To¨ro¨k T., Linde C., REVERSE Study Group.
Prevention of disease progression by cardiac resynchronization
therapy in patients with asymptomatic or mildly symptomatic left
ventricular dysfunction: insights from the European cohort of the
REVERSE trial. J Am Coll Cardiol 2009;54:1837–1846.
425. Linde C., Gold M.R., Abraham W.T., St John Sutton M., Ghio S.,
Cerkvenik J., Daubert C.. Long-term impact of cardiac
resynchronization therapy in mild heart failure: 5-year results from
the REsynchronization reVErses Remodeling in Systolic left
vEntricular dysfunction (REVERSE) study. Eur Heart J 2013;34:2592–
2599
426. Woods B., Hawkins N., Mealing S., Sutton A., Abraham W.T.,
Beshai J.F., Klein H., Sculpher M., Plummer C.J., Cowie M.R.
Individual patient data network meta-analysis of mortality effects of
implantable cardiac devices. Heart 2015; 101:1800–1806
427. Curtis A.B.,Worley S.J., Adamson P.B., Chung E.S., Niazi I.,
Sherfesee L., Shinn T, St John Sutton M.. Biventricular pacing for
atrioventricular block and systolic dysfunction.N Engl J Med
2013;368:1585–1593.
428. Brignole M., Botto G., Mont L., Iacopino S., De Marchi G.,
Oddone D., Luzi M., Tolosana J.M., Navazio A., Menozzi C. Cardiac
resynchronization therapy in patientsundergoing atrioventricular
junction ablation for permanent atrial ﬁbrillation: a randomized trial.
Eur Heart J 2011;32:2420–2429.
429. Leclercq C.,Walker S., Linde C., Clementy J., Marshall A.J.,
Ritter P., Djiane P., Mabo P., Levy T., Gadler F., Bailleul C., Daubert J-
C. Comparative effects of permanent biventricular and right-
univentricular pacing in heart failure patients with chronic atrial
ﬁbrillation. Eur Heart J 2002;23:1780–1787.

430. Stavrakis S., Garabelli P., Reynolds D.W. Cardiac
resynchronization therapy after atrioventricular junction ablation for
symptomatic atrial ﬁbrillation: a meta-analysis. Europace
2012;14:1490–1497
431. MacDonald M.R., Connelly D.T., Hawkins N.M., Steedman T.,
Payne J., Shaw M.,Denvir M., Bhagra S., Small S., Martin W.,
McMurray J.J., Petrie M.C. Radiofrequency ablation for persistent
atrial ﬁbrillation in patients with advanced heart failure and severe
left ventricular systolic dysfunction: a randomised controlled trial.
Heart 2011;97:740–747.
432. Jones D.G., Haldar S.K., Hussain W., Sharma R., Francis D.P.,
Rahman-Haley S.L.,McDonagh T.A., Underwood S.R., Markides V.,
Wong T. A randomized trial to assess catheter ablation versus rate
control in the management of persistent atrial ﬁbrillation in heart
failure. J Am Coll Cardiol 2013;61:1894–1903.
433. Upadhyay G.A., Choudhry N.K., Auricchio A., Ruskin J., Singh
J.P. Cardiac resynchronization in patients with atrial ﬁbrillation: a
meta-analysis of prospective cohortstudies. J Am Coll Cardiol
2008;52:1239–1246.
434. Gasparini M., Leclercq C., Lunati M., Landolina M., Auricchio
A., Santini M., Boriani G., Lamp B., Proclemer A., Curnis A., Klersy C.,
Leyva F. Cardiac resynchronization therapy in patients with atrial
ﬁbrillation. The CERTIFY Study (Cardiac Resynchronization Therapy
in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail
2013;1:500–507
435. Gage R.M., Burns K.V., Bank A.J. Echocardiographic and clinical
response to cardiac resynchronization therapy in heart failure
patients with and without previous right ventricular pacing. Eur J
Heart Fail 2014;16:1199–1205.
436. Funck RC, Mueller H-H, Lunati M, Piorkowski C, De Roy L, Paul
V, Wittenberg M, Wuensch D, Blanc J-J. Characteristics of a large
sample of candidates for permanent ventricular pacing included in the
Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac
Desynchronization Study (BioPace). Europace 2014; 16:354–362.
437. Ruschitzka F., AbrahamW.T., Singh J.P., Bax J.J., Borer J.S.,
Brugada J., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard
P., Holzmeister J. Cardiac-resynchronization therapy in heart failure
with a narrow QRS complex. N Engl J Med 2013;369:1395–1405

438. Steffel J., Robertson M., Singh J.P., Abraham W.T., Bax J.J.,
Borer J.S., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard
P., Holzmeister J., Brugada J., Ruschitzka F. The effect of QRS duration
on cardiac resynchronization therapy in patients with a narrow QRS
complex: a subgroup analysis of the EchoCRT trial. Eur Heart J
2015;36:1983–1989
439. Zusterzeel R., Selzman K.A., Sanders W., Can˜os D.A.,
O’Callaghan K.M., Carpenter J.L., Pin˜a I.L., Strauss D.G. Cardiac
resynchronization therapy in women:US Food and Drug
Administration meta-analysis of patient-level data. JAMA Intern Med
2014;174:1340–1348
440. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom
D.S., Daubert J.P., Higgins S.L., Brown M.W.,Andrews M.L.Prophylactic
implantation of a deﬁbrillator in patients with myocardial infarction
and reduced ejection fraction. N Engl J Med 2002;346:877–883
441. Desai A.S., Fang J.C., Maisel W.H., Baughman K.L. Implantable
deﬁbrillators for the prevention of mortality in patients with
nonischemic cardiomyopathy: a meta-analysis of randomized
controlled trials. JAMA2004;292:2874–2879;
442. Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of
implantable cardioverter-deﬁbrillators. N Engl J Med 2005;353:1471–
1480
443. Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton
J.R., Hatala R., Fain E., Gent M., Connolly S.J.Prophylactic use of an
implantable cardioverter-deﬁbrillator after acute myocardial
infarction. N Engl J Med2004;351:2481–2488
444. TeinbeckG., AndresenD., SeidlK., BrachmannJ., HoffmannE.,
WojciechowskiD., Kornacewicz-JachZ., SredniawaB., LupkovicsG.,
HofgärtnerF., LubinskiA., RosenqvistM., HabetsA., WegscheiderK.,
SengesJ. Deﬁbrillatorimplantationearlyaftermyocardialinfarction. N
Engl J Med 2009;361:1427–1436
445. Steinberg B.A., AlKhatib S.M., Edwards R., Han J., Bardy G.H.,
Bigger J.T., Buxton A.E., Moss A.J., Lee K.L.,Steinman R., Dorian P.,
Hallstrom A., Cappato R., Kadish A.H., Kudenchuk P.J., Mark D.B.,
Inoue LYT, Sanders G.D.Outcomes of implantable cardioverter-
deﬁbrillator use in patients with comorbidities: results from a
combined analysis of 4 randomized clinical trials. JACC Heart Fail
2014;2:623–629

446. Raphael C.E., Finegold J.A., Barron A.J., Whinnett Z.I., Mayet
J., Linde C., Cleland JGF., Levy W.C., Francis D.P. The effect of
duration of follow-up and presence of competing risk on lifespan-gain
from implantable cardioverter deﬁbrillator therapy: who beneﬁts the
most? Eur Heart J 2015;36:1676–1688.;
447. Miller RJH., Howlett J.G., Exner D.V., Campbell P.M., Grant
ADM.,Wilton S.B. Baseline functional class and therapeutic efﬁcacy of
common heart failure interventions: a systematic review and meta-
analysis. Can J Cardiol2015;31:792–799; Hess P.L., AlKhatib S.M., Han
J.Y., Edwards R., Bardy G.H., Bigger J.T., Buxton A., Cappato R., Dorian
P.,Hallstrom A., Kadish A.H., Kudenchuk P.J., Lee K.L., Mark D.B.,
Moss A.J., Steinman R., Inoue LYT, Sanders G. Survival beneﬁt of the
primary prevention implantable cardioverter-deﬁbrillator among
older patients: does age matter? An analysis of pooled data from 5
clinical trials. Circ Cardiovasc Qual Outcomes 2015;8:179–186
448. Merchant F.M., Jones P., Wehrenberg S., Lloyd M.S., Saxon L.A.
Incidence of deﬁbrillator shocks after elective generator exchange
following uneventful ﬁrst battery life. J Am Heart Assoc
2014;3:e001289
449. Yap S-C., Schaer B.A., Bhagwandien R.E., Kuhne M., Dabiri
Abkenari L., Osswald S., Szili-Torok T., Sticherling C.,Theuns D.A.
Evaluation of the need of elective implantable cardioverter-
deﬁbrillator generator replacement in primary prevention patients
without prior appropriate ICD therapy. Heart 2014;100:1188–1192
450. Kini V., Souﬁ M.K., Deo R., Epstein A.E., Bala R., Riley M.,
Groeneveld P.W., Shalaby A., Dixit S. Appropriateness of primary
prevention implantable cardioverter-deﬁbrillators at the time of
generator replacement: are indications still met? J Am Coll Cardiol
2014;63:2388–2394.
451. Erkapic D., Sperzel J., Stiller S., Meltendorf U., Mermi J.,
Wegscheider K., Hügl B. Long-term beneﬁt of implantable
cardioverter/deﬁbrillator therapy after elective device replacement:
Results of the INcidence free SUrvival after ICD REplacement
(INSURE) trial—a prospective multicentre study. Eur Heart J
2013;34:130–137.
452. Alsheikh-Ali A.A., Homer M., Maddukuri P.V., Kalsmith B.,
Estes NAM, Link M.S. Time-dependence of appropriate implantable
deﬁbrillator therapy in patients with ischemic cardiomyopathy. J
Cardiovasc Electrophysiol2008;19:784–789

453. León Salas B, Trujillo-Martín MM, García García J, Ramallo
Fariña Y, García Quintana A, Quirós López R, Serrano-Aguilar P.
Pacing Clin Electrophysiol. 2019 Aug 9. doi: 10.1111/pace.13774
Subcutaneous implantable cardioverter-deﬁbrillator in primary and
secondary prevention of sudden cardiac death: A meta-analysis
454. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY,
Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings
JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF,
Gutterman DD, Stagg A, Burkhoff D, Hasenfuß G. A Randomized
Controlled Trial to Evaluate the Safety and Efﬁcacy of Cardiac
Contractility Modulation. JACC Heart Fail. 2018;6:874-883;
455. Abraham WT, Nademanee K, Volosin K, Krueger S, Neelagaru S,
Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R,
Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y,
Burkhoff D, Kadish A; FIX-HF-5 Investigators and Coordinators.
Subgroup analysis of a randomized controlled trial evaluating the
safety and efﬁcacy of cardiaccontractility modulation in advanced
heart failure. J Card Fail. 2011 Sep;17(9):710-7. doi:
10.1016/j.cardfail.2011.05.006. Epub 2011 Jun 22.
456. Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S,
Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R,
Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y,
Burkhoff D, Abraham WT. A randomized controlled trial evaluating
the safety and efﬁcacy of cardiac contractilitymodulation in advanced
heart failure. Am Heart J. 2011 Feb;161(2):329-337.e1-2. doi:
10.1016/j.ahj.2010.10.025.
457. Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M,
Pieske B, Misier AR, Curnis A, Böcker D, Remppis A, Kautzner J,
Stühlinger M, Leclerq C, Táborsky M, Frigerio M, Parides M, Burkhoff
D, Hindricks G. Randomized, double blind study of non-excitatory,
cardiac contractility modulation electrical impulses for symptomatic
heart failure. Eur Heart J. 2008 Apr;29(8):1019-28. doi:
10.1093/eurheartj/ehn020. Epub 2008 Feb 12
458. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA,
Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate
1000 ip left ventricular assist device. Ann Thorac Surg. 1992;53:1080-
1090.

459. Gustafsson F, Morshuis M, Zimpfer D et al, on behalf of the
ELEVATE investigators. Clinical outcomes with HeartMate 3 as a
treatment for advanced hF: First data from the European ELEVATE
Registry. Presented at the 37th ISHLT, San Diego, 2017.
460. Jorde UP, Kushwaha SS, Tootles AJ, et al. Results of the
destination therapy post-food and drug dministration approval study
with a continuous ﬂow left ventricular assist device: a prospective
study using the INTERMACS ‡ registry (Interagency Registry for
Mechanically Assisted Circulatory Support). J Am Coll Cardiol.
2014;63:1751-1757.
461. Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL,
Stevenson LW, Acker MA, Goldstein DL, Silvestry SC, Milano CA,
Timothy Baldwin J, Pinney S, Eduardo Rame J, Miller MA. Interagency
registry for mechanically assisted circulatory support (INTERMACS)
analysis of pump thrombosis in the HeartMate II left ventricular assist
device. J Heart Lung Transplant. 2014; 33:12-22
462. Mehra MR, Salerno C, Cleveland JC, et al. Health Care Resource
Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome
Study: A Randomized Controlled Trial of a Magnetically Levitated
Cardiac Pump in Advanced Heart Failure. Circulation. 2018 May 27.
pii: CIRCULATIONAHA.118.035722
463. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically
Levitated Ventricular Assist Device-Final Report. N Engl J Med. 2019
March 17.
464. Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao
V, Morshuis M, Marasco S, Beyersdorf F, Damme L, Schmitto J.
Multicenter study evaluating a fully magnetically levitated left
ventricular assist system for the treatment of advanced heart failure. J
Am Coll Cardiol. 2015.
465. Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL,
Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg
AD, Steven- son LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ,
Gelijns AC. The rematch trial: Rationale, design, and end points.
Randomized evaluation of mechanical assistance for the treatment of
congestive heart failure. Ann Thorac Surg. 1999;67:723-730.
466. Schmitto JD, Hanke JS, Rojas SV, Avsar M, Haverich A. First
implantation in man of a new magnetically levitated left ventricular
assist device (HeartMate III). J Heart Lung Transplant. 2015;34:858-

860.
467. Starling RC, Estep JD, Horstmanshof DA, Milano CA, et al;
ROADMAP Study Investigators (2017). Risk Assessment and
Comparative Effectiveness of Left Ventricular Assist Device and
Medical Management in Ambulatory Heart Failure Patients: The
ROADMAP Study 2-Year Results. JACC Heart Fail,2017; 5:518-527.
468. O’Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper
L.S, Ellis S.J., LeiferE.S.,Kraus W.E., Kitzman D.W., Blumenthal J.A.,
Rendall D.S., Miller N.H., FlegJ.L.,Schulman K.A., McKelvie R.S.,
Zannad F., Pin˜a I.L., HF-ACTION Investigators. Efﬁcacy and safety of
exercise training in patients with chronic heart failure: HF-ACTION
randomized controlled trial. JAMA 2009;301:1439–1450.
469. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H,
Lough F, Rees K, Singh S. Exercise-based rehabilitation for heart
failure. Cochrane Database Syst Rev 2014;4:CD003331
470. Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen
H-D, Duvinage A, Hoischen N, Von Oehsen K, Schwarz S, Hasenfuss G,
Halle M, Pieske B, Edelmann F. Effects of exercise training on
different quality of life dimensions in heart failure with preserved
ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol 2015;22:582–
593.
471. IsmailH, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA.
Clinical outcomes and cardiovascular responses to different exercise
training intensities in patients with heart failure: a systematic review
and meta-analysis. JACC Heart Fail 2013;1:514–522. 289
472. Piepoli MF , Conraads V, Corrà U, Dickstein K, Francis DP,
Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid J-P, Anker SD,
Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski
PP. Exercise training in heart failure: from theory to practice. A
consensus document of the Heart Failure Association and the
European Association for Cardiovascular Prevention and
Rehabilitation. Eur J Heart Fail 2011;13:347–357
473. Wang MH, Yeh ML. Respiratory training interventions improve
health status of heart failure patients: A systematic review and
network meta-analysis of randomized controlled trials. World J Clin
Cases 2019; 7(18): 2760-2775

474. Adamopoulos S, Schmid J-P, Dendale P, Poerschke D, Hansen D,
Dritsas A, и др. Combined aerobic/inspiratory muscle training vs.
aerobic training in patients with chronic heart failure: The Vent-HeFT
trial: a European prospective multicentre randomized trial. European
Journal of Heart Failure. 2014;16(5):574–82. DOI:10.1002/ejhf.70
475. Feltner C, Jones CD, Cene´ CW, Zheng Z-J, Sueta CA, Coker-
Schwimmer EJLL, Arvanitis M, Lohr KN, Middleton JC, Jonas DE.
Transitional care interventions to prevent readmissions for persons
with heart failure: a systematic review and meta-analysis. Ann Intern
Med 2014;160:774–784
476. McAlister FA, Stewart S, Ferrua S, McMurray JJ.
Multidisciplinary strategies for the management of heart failure
patients at high risk for admission: a systematic review of randomized
trials. J Am Coll Cardiol 2004;44:810–819
477. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin
HR. Comprehensive discharge planning with postdischarge support
for older patients with congestive heart failure: a meta-analysis.
JAMA 2004;291:1358–1367.
478. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged
beneﬁcial effects of a home-based intervention on unplanned
readmissions and mortality among patients with congestive heart
failure. Arch Intern Med 1999;159:257–261.
479. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N,
Handberg J, Sejr Knudsen A, Espersen G, Markenvard J, Egstrup K,
Ulriksen H, Hildebrandt PR. Extended heart failure clinic follow-up in
low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J
2013;34:432–442.
480. Luttik MLA, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes
AW, de Jong R, Linssen G, Lok DJA, Berge M, van Veldhuisen DJ. Long-
term follow-up in optimally
treated and stable heart failure patients: primary care vs. heart failure
clinic. Results of the COACH-2 study. Eur J Heart Fail 2014;16:1241–
1248
481. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics
and outcomes of patients hospitalized for heart failure in the United
States: rationale, design, and preliminary observations from the ﬁrst

100,000 cases in the Acute Decompensated Heart Failure National
Registry (ADHERE). Am Heart J 2005; 149: 209–216.
482. Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk
prediction of short-term mortality in cardiogenic shock. Eur J Heart
Fail 2015; 17: 501–509;
483. Nieminen M., Brutsaert D., Dickstain K. et al. EuroHeart Failure
Survey II (EHFS II): a survey on hospitalized acute heart failure
patients: description of population. Eur Heart J. 2006; 27 (22): 2725–
2736;
484. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood
pressure at admission, clinical characteristics, and outcomes in
patients
hospitalized
with
acute
heart
failure.
JAMA
2006;296(18):2217–26.
485. Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр
госпитализированных
пациентов
с
декомпенсацией
кровообращения
(павловский
регистр).
Сообщение
1.
Современная
клиническая
характеристика
пациента
с
декомпенсацией кровообращения. Клинические фенотипы
пациентов. Журнал сердечная недостаточность. 2014; 4 (1): 135–
141;
486. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart
failure: symptoms, patterns of onset, and contributing factors. Am J
Med 2003;114(8):625–30.
487. O"Connor CM, Stough WG, Gallup DS, Hasselblad V,
Gheorghiade M. Demographics, clinical characteristics, and outcomes
of patients hospitalized for decompensated heart failure: observations
from the IMPACT-HF registry. J Card Fail 2005;11(3):200–5;
488. Valente MA, Voors AA, Damman K, et al. Diuretic response in
acute heart failure: clinical characteristics and prognostic
signiﬁcance. Eur Heart J 2014; 35: 1284–1293
489. Shepperd S, McClaran J, Phillips CO, et al. Discharge planning
from hospital to home. Cochrane Database Syst Rev 2010;(1):
CD000313
490. Bielecka-Dabrowa A, Godoy B, Schefold JC et al.
Decompensated Heart Failure and Renal Failure: What Is the Current
Evidence? Curr Heart Fail Rep. 2018 Aug; 15(4): 224-238

491. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by
treatment among patients hospitalized with acute heart failure: the
global ALARM-HF registry using propensity-scoring methods.
Intensive Care Med 2011; 37: 290 – 301.
492. Фомин И.В., Краием Н., Поляков Д.С., и др. Понятие
стабильности течения ХСН – приемлемо ли оно для российской
практики? Кардиология. 2018. Т. 58. - №. S3 - С.55-63.]
493. Stewart S. Financial aspects of heart failure programs of care.
Eur J Heart Fail 7 (2005) 423– 428;
494. Shaﬁe AA, Tan YP, Ng CH. Systematic review of economic
burden of heart failure. Heart Fail Rev. 2018; 23(1):131-145
495. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of
randomized trials of disease management programs in heart failure.
Am J Med. 2001; 110: 378–84.3
496. Виноградова Н.Г., Жиркова М.М., Фомин И.В., Поляков Д.С.
Эффективность лечения хронической сердечной недостаточности
на амбулаторном этапе в условиях городского центра ХСН.
Журнал сердечная недостаточность. -2017. -Т.18. №4. -С.270-278.
497. Фомин И.В., Виноградова Н.Г., Фарзалиев М.И., и др.
Эффективность
наблюдения
пациентов
в
условиях
специализированного центра лечения хронической сердечной
недостаточности. Неотложная кардиология и кардиоваскулярные
риски. 2018. Т. 2. - №.1. - С. 221-229. ISSN: 2616-633X20, 21
498. Виноградова Н.Г., Поляков Д.С., Фомин И.В., Жиркова М.М.
Прогноз жизни пациентов с хронической сердечной
недостаточностью и фибрилляцией предсердий в зависимости от
контроля гемодинамических показателей и толерантности к
физической нагрузке на фоне базисной терапии. Кардиология.
2019; 59 (4S): 51-58.
500. Виноградова Н.Г. Городской центр лечения хронической
сердечной
недостаточности:
организация
работы
и
эффективность лечения пациентов с хронической сердечной
недостатосностью. Кардиология. 2019; 59 (2S): 31-39
501. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone
support or telemonitoring programmes for patients with chronic heart
failure. Cochrane Database Syst Rev. 2010; (8):CD007228.

502. Koehler F., Winkler S., Schieber M., et al. Telemedial
interventional monitoring in Heart Failure (TIM-HF), a randomized,
controlled intervention trial investigating the impact of telemedicine
on mortality in ambulatory patients with heart failure. Eur J Heart
Fail. 2010; 12: 1354-1362.
503. Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital
discharge program to decrease rehospitalization: a randomized trial.
Ann Intern Med. 2009;150(3):178-187.
504. Linden A, Butterworth S. A comprehensive hospital-based
intervention to reduce readmissions for chronically ill patients: a
randomized controlled trial. Am J Manag Care. 2014; 20(10): 783-792.
505. Wakeﬁeld BJ, Boren SA, Groves PS, Conn VS. Heart failure care
management programs: a review of study interventions and meta-
analysis of outcomes. J Cardiovasc Nurs. 2013; 28(1): 8-19.
506. Van Spall HGC., Lee SF., Xie F., et al. Effect of Patient-Centered
Transitional Care Services on Clinical Outcomes in Patients
Hospitalized for Heart Failure. The PACT-HF Randomized Clinical
Trial. JAMA. 2019; 321 (8): 753-761. doi:10.1001/jama.2019.0710
507. Sochalski J, Jaarsma T, Krumholz HM, et al. What works in
chronic care management: the case of heart failure? Health Aff
(Millwood). 2009; 28: 179–89.
508. Van Spall HGC, Rahman T, Mytton O, et al. Comparative
effectiveness of transitional care services in patients discharged from
the hospital with heart failure: a systematic review and network meta-
analysis. Eur J Heart Fail. 2017; 19(11): 1427-1443.
509. Masoudi FA. A Transitional-Care Model to Reduce
Readmissions After Heart Failure? JAMA. 2019; 321, March 22:
doi:10.1001/jama.2019.0710.
510. H.M. Krumholz, J. Amatruda, G.L Smith, et al. Randomized trial
of an education and support intervention to prevent readmission of
patients with heart failure. J Am Coll Cardiol, 39 (2002): 83-89;
511. S. Stewart, J.D. Horowitz. Home-based intervention in
congestive heart failure: long-term implications on readmission and
survival. Circulation, 105 (2002): 2861-2866

512. Беленков Ю. Н., Агеев Ф. Т., Банщиков Г. Т. и др. Влияние
специализированных форм активного амбулаторного ведения на
функциональный статус, качество жизни и показатели
гемодинамики
больных
с
выраженной
сердечной
недостаточностью. Результаты Российской программы «Шанс» //
Сердечная недостаточность. 2007; 3: 112–116;
513. Фомин И.В., Виноградова Н.Г. Организация
специализированной медицинской помощи больным с
хроничекой сердечной недостаточностью. CardioСоматика. 2017.
Т. 8. №3. С. 10-15.
514. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated
hospitalizations predict mortality in the community population with
heart failure. American Heart Journal. 2007;154 (2):260–6.
DOI:10.1016 / j. ahj. 2007.01.041//
515. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo
Leiro M, Drozdz J et al. EURObservational Research Programme:
regional differences and 1-year follow-up results of the Heart Failure
Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15 (7):808–17.
DOI:10.1093 / eurjhf / hft050.
516. Fonarow G., Stough W., Abraham W., Albert N., Gheorghiade
M., Greenberg B., O’Connor C., Sun J., Yancy C. and Young J.
Characteristics, Treatments, and Outcomes of Patients With
Preserved Systolic Function Hospitalized for Heart Failure. Journal of
the American College of Cardiology. 2007; 50(8):768-777.
https://doi.org/10.1016/j.jacc.2007.04.064.
517. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and
outcomes of infection-related hospital admissions of heart failure
patients.
PLoS
One.
2013;8:e72476.
doi:
10.1371/journal.pone.0072476.
518. Fonarow GC, Abraham WT, Albert NM; et al. Factors Identiﬁed
as Precipitating Hospital Admissions for Heart Failure and Clinical
Outcomes. Findings From OPTIMIZE-HF. Arch Intern Med.
2008;168(8):847-854. doi:10.1001/archinte.168.8.847.
519. Sandoval C, Walter SD, Krueger P, Smieja M, Smith A, Yusuf S,
Loeb MB. Risk of hospitalization during inﬂuenza season among a
cohort of patients with congestive heart failure.Epidemiol Infect.
2007; 135:574–582. doi: 10.1017/S095026880600714X

520. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J,
Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD;
PARADIGM-HF Investigators. Inﬂuenza vaccination in patients with
chronic heart failure: the PARADIGM-HF trial.JACC Heart Fail. 2016;
4:152–158. doi: 10.1016/j.jchf.2015.10.012.
521. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Inﬂuenza
vaccination and risk of hospitalization in patients with heart failure: a
self-controlled case series study.Eur Heart J. 2017; 38:326–333. doi:
10.1093/eurheartj/ehw411.
522. Kopel E, Klempfner R, Goldenberg I. Inﬂuenza vaccine and
survival in acute heart failure.Eur J Heart Fail. 2014; 16:264–270. doi:
10.1002/ejhf.14.
523. Modin, D, Jorgensen, ME, Gislason, G, Jensen, JS, Kober, L,
Claggett, B, Hegde, SM, Solomon, SD, Torp-Pedersen, C, Biering-
Sørensen, T. Inﬂuenza vaccine in heart failure: cumulative number of
vaccinations, frequency, timing, and survival: a Danish Nationwide
Cohort
Study.
Circulation.
2019:139:575–589.
doi:
10.1161/CIRCULATIONAHA.118.036788.
524. Antunes MM, Duarte GS, Brito D, Borges M, Costa J, Ferreira JJ,
Pinto FJ, Caldeira D, Pneumococcal vaccination in adults at very high
risk or with established cardiovascular disease: systematic review and
meta-analysis. European Heart Journal - Quality of Care and Clinical
Outcomes, qcaa030, https://doi.org/10.1093/ehjqcco/qcaa030.
525. Renal syndromes associated with nonsteroidal
antiinﬂammatory drugs. Clive DM, Stoff JS N Engl J Med. 1984 Mar 1;
310(9):563-72ю
526. Prostaglandins in severe congestive heart failure. Relation to
activation of the renin--angiotensin system and hyponatremia. Dzau
VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH N Engl
J Med. 1984 Feb 9; 310(6):347-52.
527. Van den Ouweland FA, Gribnau FW, Meyboom RH Congestive
heart failure due to nonsteroidal anti-inﬂammatory drugs in the
elderly Age Ageing. 1988 Jan; 17(1):8-16.
528. Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Anti
‐
inﬂammatory Drugs and Risk of Incident Heart Failure: A Systematic
Review and Meta
‐analysis of Observational Studies Clin Cardiol. 2016
Feb; 39(2):111-8. Epub 2015 Dec 31.

529. Doukky R, Avery E, Mangla A, Collado FM, Ibrahim Z, Poulin
M-F, et al. Impact of Dietary Sodium Restriction on Heart Failure
Outcomes. JACC: Heart Failure. 2016;4 (1):24–35. DOI:10.1016 / j.
jchf. 2015.08.007
530. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P.
Normalsodium diet compared with low-sodium diet in compensated
congestive heart failure: is sodium an old enemy or a new friend?
Clinical Science. 2008;114 (3):221–30. DOI:10.1042 / CS2007019
531. De Vecchis R, Paccone A , Di Maio M. Effects of a Restricted
Water Intake on Various Clinical and Laboratory Outcomes in Patients
With Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
Minerva Cardioangiol . 2020 Feb 20. doi: 10.23736/S0026-
4725.20.05072-0. Online ahead of print.
532. Walsh CR, Larson MG, Evans JC, Djousse L, Ellison RC, Vasan
RS, et al. Alcohol Consumption and Risk for Congestive Heart Failure
in the Framingham Heart Study. Annals of Internal Medicine.
2002;136 (3):181. DOI:10.7326 / 0003-4819-136-3-200202050-00005.
533. Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-
La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS,
Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J,
Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schafer
A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction,
injury and failure in acute heart failure: from pathophysiology to
diagnosis and management. Eur J Heart Fail 2017;19:821–836.
534. Bjork JB, Alton KK, Georgiopoulou VV, Butler J, Kalogeropoulos
AP. Deﬁning advanced heart failure: a systematic review of criteria
used in clinical trials. J Card Fail 2016;22: 569–577
535. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH,
Stevenson LW. Clinical assessment identiﬁes hemodynamic proﬁles
that predict outcomes in patients admitted with heart failure. J Am
Coll Cardiol 2003;41:1797–1804
536. Chakko S,Woska D, Martinez H, de Marchena E, Futterman L,
Kessler KM, Myerberg RJ. Clinical, radiographic, and hemodynamic
correlations in chronic congestive heart failure: conﬂicting results
may lead to inappropriate care. Am J Med 1991;90:353–359

537. Hummel YM, Liu LCY, Lam CS, Fonseca-Munoz DF, Damman K,
Rienstra M, van der Meer P, Rosenkranz S, van Veldhuisen DJ, Voors
AA, Hoendermis ES. Echocardiographic estimation of left ventricular
and pulmonary pressures in patients with heart failure and preserved
ejection fraction: a study utilizing simultaneous echocardiography
and invasive measurements. Eur J Heart Fail 2017;19:1651–1660
538. Quinones MA, Greenberg BH, Kopelen HA, Koilpillai C,
Limacher MC, Shindler DM, Shelton BJ, Weiner DH.
Echocardiographic predictors of clinical outcome in patients with left
ventricular dysfunction enrolled in the SOLVD registry and trials:
signiﬁcance of left ventricular hypertrophy. Studies of Left Ventricular
Dysfunction. J Am Coll Cardiol 2000;35:1237–1244;
539. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N,
Hester A, Anand I, Cohn JN. Severity of left ventricular remodeling
deﬁnes outcomes and response to therapy in heart failure: Valsartan
Heart Failure Trial (Val-HeFT) echocardiographic data. J Am Coll
Cardiol 2004;43:1892–1897
540. Rossi A, Cicoira M, Bonapace S, Golia G, Zanolla L,
Franceschini L, Vassanelli C. Left atrial volume provides independent
and incremental information compared with exercise tolerance
parameters in patients with heart failure and left ventricular systolic
dysfunction. Heart 2007;93:1420–1425
541. Paraskevaidis IA, Ikonomidis I, Simitsis P, Parissis J, Stasinos V,
Makavos G, Lekakis J. Multidimensional contractile reserve predicts
adverse outcome in patients with severe systolic heart failure: a 4-
year follow-up study. Eur J Heart Fail 2017;19:846–861
542. Lichtenstein D, Lascols N, Mezière G, Gepner A: Ultrasound
diagnosis of alveolar consolidation in the critically ill. Intensive Care
Med 2004, 30:276–281;
543. Platz E, Lewis EF, Uno H, et al. Detection and prognostic value
of pulmonary congestion by lung ultrasound in ambulatory heart
failure patients. Eur Heart J 2016;37:1244–51
544. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB,
Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B,
Zimmer C, Orlandi C, Gheorghiade M. Clinical implications of QRS
duration in patients hospitalized with worsening heart failure and
reduced left ventricular ejection fraction. JAMA 2008; 299:2656–2666

545. Hawkins NM,Wang D, McMurray JJ, Pfeffer MA, Swedberg K,
Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG.
Prevalence and prognostic implications of electrocardiographic left
ventricular hypertrophy in heart failure: evidence from the CHARM
programme. Heart 2007;93: 59–64
546. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF,
Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T,
Mueller C, DeFilippi C, Harjola V-P, Thiele H, Piepoli MF, Metra M,
Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM,
Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G.
Recommendations on pre-hospital and early hospital management of
acute heart failure: a consensus paper from the HFA of the ESC, the
European Society of Emergency Medicine and the Society of Academic
Emergency Medicine. Eur J Heart Fail 2015;17:544–558
547. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO,
DiCapua P, Krumholz HM. Renal impairment and outcomes in heart
failure: systematic review and meta-analysis. J Am Coll Cardiol
2006;47:1987–1996
548. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac
troponin I is associated with impaired hemodynamics, progressive left
ventricular dysfunction, and increased mortality rates in advanced
heart failure. Circulation 2003;108:833–838
549. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR,
Pitzus AE, Garcia EH, Obregon R, Brizuela M, Barbagelata A. Ongoing
myocardial injury in stable severe heart failure: value of cardiac
troponin T monitoring for high-risk patient identiﬁcation. Circulation
2004;110:2376–2382.
550. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-
type natriuretic peptide and cardiac troponin levels to predict in-
hospital mortality from ADHERE. Am J Cardiol. 2008;101:231–7.
551. Peacock WFI, De Marco T, Fonarow GC, et al. Cardiac troponin
and outcome in acute heart failure. N Engl J Med. 2008;358:2117–26
552. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M.
Admission B-type natriuretic peptide levels and in-hospital mortality
in acute decompensated heart failure. J Am Coll Cardiol
2007;49:1943–1950

553. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T,
Garrido IP, Bonaque JC, Pastor-Perez F, Valdes M, Januzzi JL. Soluble
ST2, high-sensitivity troponin T- and N-terminal pro-B-type
natriuretic peptide: complementary role for risk stratiﬁcation in
acutely decompensated heart failure. Eur J Heart Fail 2011;13:718–
725.
554. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-
B-type natriuretic peptide testing for the diagnosis or exclusion of
heart failure in patients with acute symptoms. Am J Cardiol.
2008;101:29–38.
555. Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental
value of natriuretic peptide measurement in acute decompensated
heart failure (ADHF): a systematic review. Heart Fail Rev.
2014;19:507–19
556. van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness
of intermediate amino-terminal pro-brain natriuretic peptide
concentrations for diagnosis and prognosis of acute heart failure. Am
J Cardiol. 2006;98:386–90.
557. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-
brain natriuretic peptide predicts outcome after hospital discharge in
heart failure patients. Circulation. 2004;110:2168–74.
558. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type
natriuretic peptide assay for identifying patients at high risk of re-
admission after decompensated heart failure. J Am Coll Cardiol.
2004;43:635–41.
559. Maisel A, Hollander JE, Guss D, et al. Primary results of the
Rapid Emergency Department Heart Failure Outpatient Trial
(REDHOT). A multicenter study of B-type natriuretic peptide levels,
emergency department decision making, and outcomes in patients
presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–
33.
560. Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM,
Metra M, Bayés-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP,
Pinto YM, Kok WE. Challenging the two concepts in determining the
appropriate pre-discharge N-terminal pro-brain natriuretic peptide
treatment target in acute decompensated heart failure patients:
absolute or relative discharge levels? Eur J Heart Fail 2015;17:936–944

561. Park M, Sangean MC, Volpe MDS, Feltrim MIZ, Nozawa E, Leite
PF, Passos Amato MB, Lorenzi-Filho G. Randomized, prospective trial
of oxygen, continuous positive airway pressure, and bilevel positive
airway pressure by face mask in acute cardiogenic pulmonary edema.
Crit Care Med 2004;32:2407–2415
562. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV.
Potentially detrimental cardiovascular effects of oxygen in patients
with chronic left ventricular systolic dysfunction. Heart 2010;96:533–
538
563. Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive
pressure ventilation (CPAP or bilevel NPPV) for cardiogenic
pulmonary oedema. Cochrane Database Syst Rev 2013;5: CD005351
564. Weng C-L, Zhao Y-T, Liu Q-H, Fu C-J, Sun F, Ma Y-L, Chen Y-
W, He Q-Y. Meta-analysis: noninvasive ventilation in acute
cardiogenic pulmonary edema. Ann Intern Med 2010;152:590–600
565. Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon
S, Crane S, Elliott M, Nicholl J. A multicentre randomised controlled
trial of the use of continuous positive airway pressure and non-
invasive positive pressure ventilation in the early treatment of
patients presenting to the emergency department with severe acute
cardiogenic pulmonary oedema: the 3CPO Trial. Health Technol
Assess 2009;13:1–106
566. Wuerz RC, Meador SA. Effects of prehospital medications on
mortality and length of stay in congestive heart failure. Ann Emerg
Med 1992;21:669–674
567. Metra M, Felker GM, Zaca` V, Bugatti S, Lombardi C, Bettari L,
Voors AA, Gheorghiade M, Dei Cas L. Acute heart failure: multiple
clinical proﬁles and mechanisms require tailored therapy. Int J Cardiol
2010;144:175–179
568. Wakai A, McCabe A, Kidney R, B,rooks SC, Seupaul RA, Diercks
DB, Salter N, Fermann GJ, Pospisil C. Nitrates for acute heart failure
syndromes. Cochrane Database Syst Rev 2013;8:CD005151
569. Ify R Mordi , Bernadet T Santema, Mariëlle Kloosterman , Anna-
Maria Choy, Michiel Rienstra , Isabelle van Gelder , Stefan D Anker ,
John G Cleland , Kenneth Dickstein , Gerasimos Filippatos, Pim van
der Harst, Hans L Hillege , Marco Metra , Leong L Ng , Wouter
Ouwerkerk , Piotr Ponikowski , Nilesh J Samani Dirk J van Veldhuisen

, Aeilko H Zwinderman , Faiez Zannad , Adriaan A Voors , Chim C
Lang . Prognostic signiﬁcance of changes in heart rate following
uptitration of beta-blockers in patients with sub-optimally treated
heart failure with reduced ejection fraction in sinus rhythm versus
atrial ﬁbrillation . Clin Res Cardiol. 2019 Jul;108(7):797-805. doi:
10.1007/s00392-018-1409-x. Epub 2019 Jan 4.
570. Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire
I, Richards M, Andersson B, Ezekowitz JA, Komajda M, Petrie MC,
McAlister FA, Gamble GD, Whalley GA, McMurray JJ. Is heart rate a
risk marker in patients with chronic heart failure and concomitant
atrial ﬁbrillation? Results from the MAGGIC meta-analysis. Eur J
Heart Fail 2015;17:1182–1191
571. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT,
Woosley RL. Acute treatment of recent-onset atrial ﬁbrillation and
ﬂutter with a tailored dosing regimen of intravenous amiodarone. A
randomized, digoxin-controlled study. Eur Heart J 1995;16:521–528
572. Delle Karth G, Geppert A, Neunteuﬂ T, Priglinger U, Haumer M,
Gеschwandtner M, Siostrzonek P, Heinz G. Amiodarone versus
diltiazem for rate control in critically ill patients with atrial
tachyarrhythmias. Crit Care Med 2001;29:1149–1153
573. Clemo H, Wood M, Gilligan D, Ellenbogen K. Intravenous
amiodarone for acute heart rate control in the critically ill patient
with atrial tachyarrhythmias. Am J Cardiol 1998;81:594–598.
574. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of
beta-blocker withdrawal in acute decompensated heart failure: a
systematic review and meta-analysis. JACC Heart Fail 2015;3: 647–
653.
575. Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD,
Filippatos GS. Physicians’ guideline adherence is associated with
better prognosis in outpatients with heart failure with reduced
ejection fraction: the QUALIFY international registry. Eur J Heart Fail
2017;19:1414–1423; Ertl G, Angermann CE, Bekeredjian R, Beyersdorf
F, Güder G, Gummert J, Katus HA, Kindermann I, Pauschinger M,
Perings S, Raake PWJ, Störk S, Scheidt Wv, Welz S, Böhm M. Aufbau
und Organisation von Herzinsufﬁzienz-Netzwerken (HF-NETs) und
Herzinsufﬁzienz-Einheiten (“Heart Failure Units”, HFUs) zur
Optimierung der Behandlung der akuten und chronischen
Herzinsufﬁzienz. Der Kardiologe 2016;10:222–235

576. Voors AA, OuwerkerkW, Zannad F, van Veldhuisen DJ, Samani
NJ, Ponikowski P, Ng LL, Metra M, Ter Maaten JM, Lang CC, Hillege
HL, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD,
Zwinderman AH. Development and validation of multivariable models
to predict mortality and hospitalization in patients with heart failure.
Eur J Heart Fail 2017;19:627–634
577. Lund LH, Aaronson KD, Mancini DM. Predicting survival in
ambulatory patients with severe heart failure on beta-blocker therapy.
Am J Cardiol 2003;92:1350–1354
578. Wachter R Senni M, Belohlavek J, Straburzynska-Migaj E, Witte
KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez
A, Chaaban S, Bøhmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn
E, Al Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H.
Initiation of sacubitril/valsartan in haemodynamically stabilised heart
failure patients inhospital or early after discharge: Primary results of
the randomised TRANSITION study. Eur J Heart Fail. 2019
doi:10.1002/ejhf.1498
579. Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk
stratiﬁcation for inhospital mortality in acutely decompensated heart
failure classiﬁcation and regression tree analysis. JAMA
2015;293:572–580
580. Thorvaldsen T, Benson L, Stahlberg M, Dahlstrom U, Edner M,
Lund LH. Triage of patients with moderate to severe heart failure: who
should be referred to a heart failure center? J Am Coll Cardiol
2014;63:661–671.
581. Jonkman NH, Westland H, Groenwold RH, Ågren S, Atienza F,
Blue L, Bruggink-André de la Porte PW, DeWalt DA, Hebert PL, Heisler
M, Jaarsma T, Kempen GI, Leventhal ME, Lok DJ, Mårtensson J, Muñiz
J, Otsu H, Peters-Klimm F, Rich MW, Riegel B, Strömberg A, Tsuyuki
RT, van Veldhuisen DJ, Trappenburg JC, Schuurmans MJ, Hoes AW. Do
Self-Management Interventions Work in Patients With Heart Failure?
An Individual Patient Data Meta-Analysis. Circulation. 2016 Mar
22;133:1189-98
582. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K,
Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng
LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M,
Zwinderman AH. Determinants and clinical outcome of uptitration of
ACE-inhibitors and beta-blockers in patients with heart failure: a
prospective European study. Eur Heart J. 2017;38:1883-1890

583. Iakobishvili Z, Cohen E, Garty M, Behar S, Shotan A, Sandach
A, Gottlieb S, Mager A, Battler A, Hasdai D. Use of intravenous
morphine for acute decompensated heart failure in patients with and
without acute coronary syndromes. Acute Card Care 2011;13:76–80
584. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G,
Emerman CL. Morphine and outcomes in acute decompensated heart
failure: an ADHERE analysis. Emerg Med J 2008;25:205–209
585. Publication Committee for the VMAC Investigators
(Vasodilatation in the Management of Acute CHF). Intravenous
nesiritide vs nitroglycerin for treatment of decompensated congestive
heart failure: a randomized controlled trial. JAMA 2002;287:1531–
1540
586. Felker GM, Lee KL, Bull DA, Redﬁeld MM, Stevenson LW,
Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Oﬁli EO, Anstrom
KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH,
Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E,
O’Connor CM. Diuretic strategies in patients with acute
decompensated heart failure. N Engl J Med 2011;364:797–805
587. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop
diuretics with thiazide-type diuretics in heart failure. J Am Coll
Cardiol 2010;56:1527–1534
588. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D,
Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent J-L.
Comparison of dopamine and norepinephrine in the treatment of
shock. N Engl J Med 2010;362:779–789.
589. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci
WS, Massie BM, O’Connor CM, Pina I, Quigg R, Silver MA,
Gheorghiade M. Short-term intravenous milrinone for acute
exacerbation of chronic heart failure: a randomized controlled trial.
JAMA 2002;287:1541–1547
590. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J,
Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B,
Sarapohja T. Effect of levosimendan on the short-term clinical course
of patients with acutely decompensated heart failure. JACC Heart Fail
2013;1:103–111

591. O’Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE,
Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M,
Califf RM. Continuous intravenous dobutamine is associated with an
increased risk of death in patients with advanced heart failure:
insights from the Flolan International Randomized Survival Trial
(FIRST). Am Heart J 1999;138(1 Pt 1):78–86
592. Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization
after intermittent levosimendan treatment in advanced heart failure
patients: a meta-analysis of randomized trials. ESC Heart Fail
2017;4:595–604
593. Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G,
Pasin L, Zangrillo A, Landoni G. The effect of inotropes and
vasopressors on mortality: a meta-analysis of randomized clinical
trials. Br J Anaesth 2015;115:656–675
594. Dentali F, Douketis JD, Gianni M, LimW, Crowther M. Meta-
analysis: anticoagulant prophylaxis to prevent symptomatic venous
thromboembolism in hospitalized medical patients. Ann Intern Med
2007;146:278–288
595. Sintek MA, Gdowski M, Lindman BR, Nassif M, Lavine KJ,
Novak E, Bach RG, Silvestry SC, Mann DL, Joseph SM. Intra-aortic
balloon counterpulsation in patients with chronic heart failure and
cardiogenic shock: clinical response and predictors of stabilization. J
Card Fail 2015;21:868–876; Saffarzadeh A, Bonde P. Options for
temporary mechanical circulatory support. J Thorac Dis 2015;7:2102–
2111
596. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks
EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID,
Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CA.
Intrapericardial Left Ventricular Assist Device for Advanced Heart
Failure. N Engl J Med. 2017;376:451-460.
597. Mehra MR, Goldstein DJ, Uriel N, Cleveland JC Jr, Yuzefpolskaya
M, Salerno C, Walsh MN, Milano CA, Patel CB, Ewald GA, Itoh A, Dean
D, Krishnamoorthy A, Cotts WG, Tatooles AJ, Jorde UP, Bruckner BA,
Estep JD, Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S,
Skipper ER, O"Connell JB, Heatley G, Sood P, Naka Y; MOMENTUM 3
Investigators. Two-Year Outcomes with a Magnetically Levitated
Cardiac Pump in Heart Failure. N Engl J Med. 2018;378:1386-1395.

598. John R, Long JW, Massey HT, et al. Outcomes of a multicenter
trial of the Levitronix CentriMag ventricular assist system for short-
term circulatory support. J Thorac Cardiovasc Surg. 2011; 141(4):932-
939.
599. Riebandt J, Haberl T, Mahr S, Laufer G, Rajek A, Steinlechner B,
Schima H, Zimpfer D. Preoperative patient optimization using
extracorporeal life support improves outcomes of INTERMACS Level I
patients receiving a permanent ventricular assist device. Eur J
Cardiothorac Surg. 2014 Sep; 46(3):486-92; discussion 492. doi:
10.1093/ejcts/ezu093. Epub 2014 Mar 18
600. Беленков Ю.Н., Мареев В.Ю. Принципы рационального
лечения хронической сердечной недостаточности. -М.: Медиа
Медика; 2000. 266 с.
601. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend
M, Jones NL, et al. The 6-minute walk: a new measure of exercise
capacity in patients with chronic heart failure. Can Med Assoc J.
1985;132(8):919
602. Enright PL. The six-minute walk test. Respir Care.
2003;48(8):783–5.
603. Faggiano P, D’Aloia A, Gualeni A, Brentana L, Cas LD. The 6
minute walking test in chronic heart failure: indications,
interpretation and limitations from a review of the literature. Eur J
Heart Fail. 2004;6(6):687–91.
604. Zielińska D, Bellwon J, Rynkiewicz A, Elkady MA. Prognostic
value of the six-minute walk test in heart failure patients undergoing
cardiac surgery: a literature review. Rehabil Res Pract. 2013; doi:
10.1155/2013/965494.
605. Ingle L, Cleland JG, Clark AL. The long-term prognostic
signiﬁcance of 6-minute walk test distance in patients with chronic
heart failure. Biomed Res Int. 2014;2014:505969
606. Ingle L, Cleland JG, Clark AL. The relation between repeated 6-
minute walk test performance and outcome in patients with chronic
heart failure. Ann Phys Rehabil Med. 2014;57(4):244–53
607. Pollentier B, Irons SL, Benedetto CM, DiBenedetto AM, Loton
D, Seyler RD, et al. Examination of the six minute walk test to
determine functional capacity in people with chronic heart failure: a

systematic review. Cardiopulm Phys Ther J. 2010;21(1):13–21
608. Palau P, Domínguez E, Núñez E, Sanchis J, Santas E, Núñez J.
Six-minute walk test in moderate to severe heart failure with
preserved ejection fraction: useful for functional capacity assessment?
Int J Cardiol. 2016;203:800–2
609. Forman DE, Fleg JL, Kitzman DW, Brawner CA, Swank AM,
McKelvie RS, et al. 6-min walk test provides prognostic utility
comparable to cardiopulmonary exercise testing in ambulatory
outpatients with systolic heart failure. J Am Coll Cardiol.
2012;60(25):2653–61
610. Kaminsky LA, Tuttle MS. Functional assessment of heart
failure patients. Heart Fail Clin. 2015;11(1):29–36

жүктеу/скачать 1.54 Mb.

Достарыңызбен бөлісу:

1 ... 69 70 71 72 73 74 75 76 ... 88